EP2220232B1 - Succinic acid production in a eukaryotic cell - Google Patents
Succinic acid production in a eukaryotic cell Download PDFInfo
- Publication number
- EP2220232B1 EP2220232B1 EP08851178.7A EP08851178A EP2220232B1 EP 2220232 B1 EP2220232 B1 EP 2220232B1 EP 08851178 A EP08851178 A EP 08851178A EP 2220232 B1 EP2220232 B1 EP 2220232B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- succinic acid
- nucleotide sequence
- seq
- cell according
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 title claims abstract description 220
- 239000001384 succinic acid Substances 0.000 title claims abstract description 101
- 210000003527 eukaryotic cell Anatomy 0.000 title claims abstract description 63
- 238000004519 manufacturing process Methods 0.000 title abstract description 56
- 102000019259 Succinate Dehydrogenase Human genes 0.000 claims abstract description 86
- 108010012901 Succinate Dehydrogenase Proteins 0.000 claims abstract description 86
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 77
- 239000002773 nucleotide Substances 0.000 claims abstract description 73
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 45
- 230000001419 dependent effect Effects 0.000 claims abstract description 31
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 24
- 230000008569 process Effects 0.000 claims abstract description 21
- 238000006243 chemical reaction Methods 0.000 claims abstract description 20
- 241000233866 Fungi Species 0.000 claims abstract description 13
- 239000001530 fumaric acid Substances 0.000 claims abstract description 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 76
- 230000014509 gene expression Effects 0.000 claims description 69
- 108010026217 Malate Dehydrogenase Proteins 0.000 claims description 68
- 102000013460 Malate Dehydrogenase Human genes 0.000 claims description 68
- 210000004027 cell Anatomy 0.000 claims description 66
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 102000004190 Enzymes Human genes 0.000 claims description 37
- 108090000790 Enzymes Proteins 0.000 claims description 37
- 241000228245 Aspergillus niger Species 0.000 claims description 31
- 108010053763 Pyruvate Carboxylase Proteins 0.000 claims description 19
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 claims description 18
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 18
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 16
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 15
- 239000001630 malic acid Substances 0.000 claims description 15
- 235000011090 malic acid Nutrition 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 claims description 12
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 11
- 102000016862 Dicarboxylic Acid Transporters Human genes 0.000 claims description 11
- 108010092943 Dicarboxylic Acid Transporters Proteins 0.000 claims description 11
- 210000000172 cytosol Anatomy 0.000 claims description 11
- 238000000855 fermentation Methods 0.000 claims description 11
- 230000004151 fermentation Effects 0.000 claims description 11
- 241000228212 Aspergillus Species 0.000 claims description 10
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 9
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 229930029653 phosphoenolpyruvate Natural products 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 3
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 claims 1
- 241000223093 Trypanosoma sp. Species 0.000 claims 1
- 239000013598 vector Substances 0.000 description 47
- 108020004705 Codon Proteins 0.000 description 43
- 108020004414 DNA Proteins 0.000 description 43
- 241000223105 Trypanosoma brucei Species 0.000 description 41
- 229940088598 enzyme Drugs 0.000 description 34
- 239000013612 plasmid Substances 0.000 description 33
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 31
- 239000013604 expression vector Substances 0.000 description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 27
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 27
- 239000008103 glucose Substances 0.000 description 27
- 230000002018 overexpression Effects 0.000 description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 description 26
- 230000009466 transformation Effects 0.000 description 26
- 230000001965 increasing effect Effects 0.000 description 25
- 150000007523 nucleic acids Chemical group 0.000 description 24
- 108700005078 Synthetic Genes Proteins 0.000 description 23
- 230000002438 mitochondrial effect Effects 0.000 description 22
- 108010036781 Fumarate Hydratase Proteins 0.000 description 21
- 102100036160 Fumarate hydratase, mitochondrial Human genes 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 230000037430 deletion Effects 0.000 description 19
- 238000012217 deletion Methods 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 241000948980 Actinobacillus succinogenes Species 0.000 description 16
- 230000012010 growth Effects 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 101100001031 Acetobacter aceti adhA gene Proteins 0.000 description 13
- 101150021974 Adh1 gene Proteins 0.000 description 13
- 101150047761 sdhA gene Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000008685 targeting Effects 0.000 description 13
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 240000005384 Rhizopus oryzae Species 0.000 description 11
- 101150087371 gpd1 gene Proteins 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 230000000858 peroxisomal effect Effects 0.000 description 11
- 101150078509 ADH2 gene Proteins 0.000 description 10
- 101150026777 ADH5 gene Proteins 0.000 description 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
- 101100460671 Aspergillus flavus (strain ATCC 200026 / FGSC A1120 / IAM 13836 / NRRL 3357 / JCM 12722 / SRRC 167) norA gene Proteins 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 241000029538 [Mannheimia] succiniciproducens Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 210000001938 protoplast Anatomy 0.000 description 9
- -1 CYC1 Proteins 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 101001033820 Homo sapiens Malate dehydrogenase, mitochondrial Proteins 0.000 description 8
- 102100039742 Malate dehydrogenase, mitochondrial Human genes 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 108010078791 Carrier Proteins Proteins 0.000 description 7
- 102100036669 Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic Human genes 0.000 description 7
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 238000012239 gene modification Methods 0.000 description 7
- 230000005017 genetic modification Effects 0.000 description 7
- 235000013617 genetically modified food Nutrition 0.000 description 7
- 239000013587 production medium Substances 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 229930182830 galactose Natural products 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102100038910 Alpha-enolase Human genes 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 101000882335 Homo sapiens Alpha-enolase Proteins 0.000 description 5
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- VLMZMRDOMOGGFA-WDBKCZKBSA-N festuclavine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C)=C3C2=CNC3=C1 VLMZMRDOMOGGFA-WDBKCZKBSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 101150073906 gpdA gene Proteins 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000001965 potato dextrose agar Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 101150108347 sdhB gene Proteins 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- XHLUWCXVWCBOPP-MERQFXBCSA-N (2s)-1-(2-aminoacetyl)-n-(4-nitrophenyl)pyrrolidine-2-carboxamide;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.NCC(=O)N1CCC[C@H]1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 XHLUWCXVWCBOPP-MERQFXBCSA-N 0.000 description 3
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 108010084185 Cellulases Proteins 0.000 description 3
- 102000005575 Cellulases Human genes 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 241001293415 Mannheimia Species 0.000 description 3
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 3
- 108010035235 Phleomycins Proteins 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 101150069003 amdS gene Proteins 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000012262 fermentative production Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 229940049920 malate Drugs 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229920002961 polybutylene succinate Polymers 0.000 description 3
- 239000004631 polybutylene succinate Substances 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 241000722955 Anaerobiospirillum Species 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 2
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 101710086812 Glycerol-3-phosphate dehydrogenase 1 Proteins 0.000 description 2
- 229920002488 Hemicellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101150019925 MDH2 gene Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 101100465559 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRE7 gene Proteins 0.000 description 2
- 101000615995 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Malic acid transport protein Proteins 0.000 description 2
- 101000616000 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Putative malic acid transport protein Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 241000223104 Trypanosoma Species 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical class O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 101150076896 pts1 gene Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- GUGNSJAORJLKGP-UHFFFAOYSA-K sodium 8-methoxypyrene-1,3,6-trisulfonate Chemical compound [Na+].[Na+].[Na+].C1=C2C(OC)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 GUGNSJAORJLKGP-UHFFFAOYSA-K 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000011044 succinic acid Nutrition 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- CYNAPIVXKRLDER-LBPRGKRZSA-N (2s)-2-benzamido-3-(4-hydroxy-3-nitrophenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)C=1C=CC=CC=1)C1=CC=C(O)C([N+]([O-])=O)=C1 CYNAPIVXKRLDER-LBPRGKRZSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FVTWJXMFYOXOKK-UHFFFAOYSA-N 2-fluoroacetamide Chemical compound NC(=O)CF FVTWJXMFYOXOKK-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000131104 Actinobacillus sp. Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101710187578 Alcohol dehydrogenase 1 Proteins 0.000 description 1
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000722954 Anaerobiospirillum succiniciproducens Species 0.000 description 1
- 101000600602 Aspergillus flavus (strain ATCC MYA-384 / AF70) Endopolygalacturonase A Proteins 0.000 description 1
- 101000600608 Aspergillus flavus (strain ATCC MYA-384 / AF70) Endopolygalacturonase B Proteins 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241001370055 Aspergillus niger CBS 513.88 Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000722885 Brettanomyces Species 0.000 description 1
- 244000027711 Brettanomyces bruxellensis Species 0.000 description 1
- 235000000287 Brettanomyces bruxellensis Nutrition 0.000 description 1
- 244000197813 Camelina sativa Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 101100409047 Chlorobaculum tepidum (strain ATCC 49652 / DSM 12025 / NBRC 103806 / TLS) ppk2 gene Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108700034430 EC 4.1.1.38 Proteins 0.000 description 1
- 101150015836 ENO1 gene Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 101150038242 GAL10 gene Proteins 0.000 description 1
- 101150108358 GLAA gene Proteins 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 102100039555 Galectin-7 Human genes 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101000608772 Homo sapiens Galectin-7 Proteins 0.000 description 1
- 101001072574 Homo sapiens Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic Proteins 0.000 description 1
- 101001056308 Homo sapiens Malate dehydrogenase, cytoplasmic Proteins 0.000 description 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 101000951145 Homo sapiens Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Proteins 0.000 description 1
- 241000223198 Humicola Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 102100023162 L-serine dehydratase/L-threonine deaminase Human genes 0.000 description 1
- 108010043075 L-threonine 3-dehydrogenase Proteins 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- 102100026475 Malate dehydrogenase, cytoplasmic Human genes 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229910004616 Na2MoO4.2H2 O Inorganic materials 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 1
- 241000235652 Pachysolen Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000228150 Penicillium chrysogenum Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010077056 Peroxisomal Targeting Signal 2 Receptor Proteins 0.000 description 1
- 102000009913 Peroxisomal Targeting Signal 2 Receptor Human genes 0.000 description 1
- 108010085186 Peroxisomal Targeting Signals Proteins 0.000 description 1
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 101710104378 Putative malate oxidoreductase [NAD] Proteins 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 101001126848 Rhizobium radiobacter Polygalacturonase Proteins 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 101100010928 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) tuf gene Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235072 Saccharomyces bayanus Species 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 101000861374 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Fumarate reductase 1 Proteins 0.000 description 1
- 101000983319 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Fumarate reductase 2 Proteins 0.000 description 1
- 235000018370 Saccharomyces delbrueckii Nutrition 0.000 description 1
- 244000253911 Saccharomyces fragilis Species 0.000 description 1
- 235000018368 Saccharomyces fragilis Nutrition 0.000 description 1
- 241000582914 Saccharomyces uvarum Species 0.000 description 1
- 101000983320 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Fumarate reductase Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241001648296 Succinimonas Species 0.000 description 1
- 101150001810 TEAD1 gene Proteins 0.000 description 1
- 101150074253 TEF1 gene Proteins 0.000 description 1
- 241000953555 Theama Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 241000235006 Torulaspora Species 0.000 description 1
- 244000288561 Torulaspora delbrueckii Species 0.000 description 1
- 235000014681 Torulaspora delbrueckii Nutrition 0.000 description 1
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 241000311098 Yamadazyma Species 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 241000235017 Zygosaccharomyces Species 0.000 description 1
- 241000235029 Zygosaccharomyces bailii Species 0.000 description 1
- 241000319304 [Brevibacterium] flavum Species 0.000 description 1
- 241000512905 [Candida] sonorensis Species 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 101150102866 adc1 gene Proteins 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000009015 carbon catabolite repression of transcription Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 101150095733 gpsA gene Proteins 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 229940031154 kluyveromyces marxianus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FDEIWTXVNPKYDL-UHFFFAOYSA-N sodium molybdate dihydrate Chemical compound O.O.[Na+].[Na+].[O-][Mo]([O-])(=O)=O FDEIWTXVNPKYDL-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
- C12P7/46—Dicarboxylic acids having four or less carbon atoms, e.g. fumaric acid, maleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Definitions
- the present invention relates to a recombinant eukaryotic cell comprising a nucleotide sequence encoding a fumarate reductase and a process for the production of succinic acid wherein the recombinant eukaryotic cell is used.
- Succinic acid is a potential precursor for numerous chemicals.
- succinic acid can be converted into 1,4-butanediol (BDO), tetrahydrofuran, and gamma-butyrolactone.
- BDO 1,4-butanediol
- Another product derived from succinic acid is a polyester polymer which is made by linking succinic acid and BDO.
- Succinic acid is predominantly produced through petrochemical processes by hydrogenation of butane. These processes are considered harmful for the environment and costly.
- the fermentative production of succinic acid may be an attractive alternative process for the production of succinic acid, wherein renewable feedstock as a carbon source may be used.
- a number of different bacteria such as Escherichia coli, and the rumen bacteria Actinobacillus, Anaerobiospirillum, Bacteroides, Mannheimia, or Succinimonas, sp. are known to produce succinic acid. Metabolic engineering of these bacterial strains have improved the succinic acid yield and/or productivity, or reduced the by-product formation.
- EP1,672,077 discloses a Brevibacterium flavum genetically modified with fumarate reductase from Escherichia coli, which increased the succinic acid yield.
- WO2007/061590 discloses a pyruvate decarboxylase negative yeast for the production of malic acid and/or succinic acid which is transformed with a pyruvate carboxylase enzyme or a phosphoenolpyruvate carboxylase, a malate dehydrogenase enzyme, and a malic acid transporter protein (MAE).
- a pyruvate carboxylase enzyme or a phosphoenolpyruvate carboxylase a malate dehydrogenase enzyme
- MAE malic acid transporter protein
- the aim of the present invention is an alternative microorganism for the production of succinic acid.
- the aim is achieved according to the invention with a recombinant eukaryotic cell selected from the group consisting of a yeast and a filamentous fungus comprising a nucleotide sequence encoding NAD(H)-dependent fumarate reductase that catalyses the conversion of fumaric acid to succinic acid.
- the recombinant eukaryotic cell according to the present invention produces an increased amount of succinic acid compared to the amount of succinic acid produced by a wild-type eukaryotic cell.
- a eukaryotic cell according to the present invention produces at least 1.2, preferably at least 1.5, preferably at least 2 times more succinic acid than a wild-type eukaryotic cell which does not comprise the nucleotide sequence encoding NAD(H)-dependent fumarate reductase.
- a recombinant eukaryotic cell is defined as a cell which contains, or is transformed or genetically modified with a nucleotide sequence or polypeptide that does not naturally occur in the eukaryotic cell, or it contains additional copy or copies of an endogenous nucleic acid sequence.
- a wild-type eukaryotic cell is herein defined as the parental cell of the recombinant cell.
- the nucleotide sequence encoding a NAD(H)-dependent fumarate reductase that catalyses the conversion of fumaric acid to succinic acid may be a heterologous or homologous nucleotide sequence, or encodes a heterologous or homologous NAD(H)-dependent fumarate reductase, which may have been further genetically modified by mutation, disruption or deletion.
- Recombinant DNA techniques are well known in the art such as in Sambrook and Russel (2001) "Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory Press .
- nucleic acid or polypeptide molecule when used to indicate the relation between a given (recombinant) nucleic acid or polypeptide molecule and a given host organism or host cell, is understood to mean that in nature the nucleic acid or polypeptide molecule is produced by a host cell or organisms of the same species, preferably of the same variety or strain.
- heterologous when used with respect to a nucleic acid (DNA or RNA) or protein refers to a nucleic acid or protein that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differ from that in which it is found in nature.
- Heterologous nucleic acids or proteins are not endogenous to the cell into which it is introduced, but have been obtained from another cell or synthetically or recombinantly produced.
- a NAD(H)-dependent fumarate reductase according to the present invention uses NAD(H) as a cofactor, whereas most eukaryotic cells comprise a FADH 2 -dependent fumarate reductase, wherein FADH 2 is the cofactor. It was found advantageous that the eukaryotic cell comprises a nucleotide sequence encoding a NAD(H)-dependent fumarate reductase, since the NAD(H)-dependent fumarate reductase provides the cell with further options to oxidise NAD(H) to NAD + and influence the redox balance in the cell.
- the cell expresses a nucleotide sequence encoding an enzyme that catalyses the formation of succinic acid, wherein the nucleotide sequence preferably encodes a NAD(H)-dependent fumarate reductase, comprising an amino acid sequence that has at least 40%, preferably at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 97, 98, 99% sequence identity with the amino acid sequence of SEQ ID NO: 1, and/or SEQ ID NO: 3, and/or SEQ ID NO: 4, and/or SEQ ID NO: 6.
- a nucleotide sequence encoding an enzyme that catalyses the formation of succinic acid
- the nucleotide sequence preferably encodes a NAD(H)-dependent fumarate reductase, comprising an amino acid sequence that has at least 40%, preferably at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 97, 98, 99% sequence
- the nucleotide sequence encodes a NAD(H)-dependent fumarate reductase comprising the amino acid sequence of SEQ ID NO: 1, and/or SEQ ID NO: 3, and/or SEQ ID NO: 4, and/or SEQ ID NO: 6.
- Sequence identity is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. Usually, sequence identities or similarities are compared over the whole length of the sequences compared. In the art, “identity” also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences.
- Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include BLASTP and BLASTN, publicly available from NCBI and other sources ( BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894 ). Preferred parameters for amino acid sequences comparison using BLASTP are gap open 11.0, gap extend 1, Blosum 62 matrix.
- Nucleotide sequences encoding the enzymes expressed in the cell of the invention may also be defined by their capability to hybridise with the nucleotide sequences encoding a NAD(H) dependent fumarate reductase of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, and/or SEQ ID NO: 6, under moderate, or preferably under stringent hybridisation conditions.
- Stringent hybridisation conditions are herein defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and most preferably of about 200 or more nucleotides, to hybridise at a temperature of about 65°C in a solution comprising about 1 M salt, preferably 6 x SSC (sodium chloride, sodium citrate) or any other solution having a comparable ionic strength, and washing at 65°C in a solution comprising about 0.1 M salt, or less, preferably 0.2 x SSC or any other solution having a comparable ionic strength.
- the hybridisation is performed overnight, i.e. at least for 10 hours and preferably washing is performed for at least one hour with at least two changes of the washing solution.
- These conditions will usually allow the specific hybridisation of sequences having about 90% or more sequence identity.
- Moderate conditions are herein defined as conditions that allow a nucleic acid sequences of at least 50 nucleotides, preferably of about 200 or more nucleotides, to hybridise at a temperature of about 45°C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at room temperature in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength.
- the hybridisation is performed overnight, i.e. at least for 10 hours, and preferably washing is performed for at least one hour with at least two changes of the washing solution.
- These conditions will usually allow the specific hybridisation of sequences having up to 50% sequence identity. The person skilled in the art will be able to modify these hybridisation conditions in order to specifically identify sequences varying in identity between 50% and 90%.
- the corresponding encoding nucleotide sequence may be adapted to optimise its codon usage to that of the chosen eukaryote host cell.
- codon optimisation are known in the art.
- a preferred method to optimise codon usage of the nucleotide sequences to that of the eukaryotic cell is a codon pair optimization technology as disclosed in WO2008/000632 .
- Codon-pair optimization is a method for producing a polypeptide in a host cell, wherein the nucleotide sequences encoding the polypeptide have been modified with respect to their codon-usage, in particular the codon-pairs that are used, to obtain improved expression of the nucleotide sequence encoding the polypeptide and/or improved production of the polypeptide.
- Codon pairs are defined as a set of two subsequent triplets (codons) in a coding sequence.
- gene refers to a nucleic acid sequence containing a template for a nucleic acid polymerase, in eukaryotes, RNA polymerase II. Genes are transcribed into mRNAs that are then translated into protein.
- nucleic acid includes reference to a deoxyribonucleotide or ribonucleotide polymer, i.e. a polynucleotide, in either single-or double-stranded form, and unless otherwise limited, encompasses known analogues having the essential nature of natural nucleotides in that they hybridize to single-stranded nucleic acids in a manner similar to naturally occurring nucleotides (e.g., peptide nucleic acids).
- a polynucleotide can be full-length or a subsequence of a native or heterologous structural or regulatory gene. Unless otherwise indicated, the term includes reference to the specified sequence as well as the complementary sequence thereof.
- polypeptide polypeptide
- peptide protein
- proteins are used interchangeably herein to refer to a polymer of amino acid residues.
- the terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.
- the essential nature of such analogues of naturally occurring amino acids is that, when incorporated into a protein, that protein is specifically reactive to antibodies elicited to the same protein but consisting entirely of naturally occurring amino acids.
- polypeptide polypeptide
- peptide protein
- modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation.
- enzyme as used herein is defined as a protein which catalyses a (bio)chemical reaction in a cell.
- nucleotide sequence encoding an enzyme is operably linked to a promoter that causes sufficient expression of the corresponding nucleotide sequence in the eukaryotic cell according to the present invention to confer to the cell the ability to produce succinic acid.
- operably linked refers to a linkage of polynucleotide elements (or coding sequences or nucleic acid sequence) in a functional relationship.
- a nucleic acid sequence is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
- a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
- promoter refers to a nucleic acid fragment that functions to control the transcription of one or more genes, located upstream with respect to the direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences known to one of skilled in the art.
- a "constitutive” promoter is a promoter that is active under most environmental and developmental conditions.
- An “inducible” promoter is a promoter that is active under environmental or developmental regulation.
- a promoter that could be used to achieve the expression of a nucleotide sequence coding for an enzyme such as NAD(H)-dependent fumarate reductase or any other enzyme introduced in the eukaryotic cell of the invention may be not native to a nucleotide sequence coding for the enzyme to be expressed, i.e. a promoter that is heterologous to the nucleotide sequence (coding sequence) to which it is operably linked.
- the promoter is homologous, i.e. endogenous to the host cell.
- nucleotide sequence encoding an enzyme comprises a terminator.
- Any terminator which is functional in the eukaryotic cell, may be used in the present invention.
- Preferred terminators are obtained from natural genes of the host cell. Suitable terminator sequences are well known in the art. Preferably, such terminators are combined with mutations that prevent nonsense mediated mRNA decay in the host cell of the invention (see for example: Shirley et al., 2002, Genetics 161:1465-1482 ).
- a nucleotide sequence encoding a NAD(H)-dependent fumarate reductase may be overexpressed to achieve a sufficient production of succinic acid by the cell.
- nucleotide sequences encoding enzymes in a eukaryotic cell of the invention there are various means available in the art for overexpression of nucleotide sequences encoding enzymes in a eukaryotic cell of the invention.
- a nucleotide sequence encoding an enzyme may be overexpressed by increasing the copy number of the gene coding for the enzyme in the cell, e.g. by integrating additional copies of the gene in the cell's genome, by expressing the gene from a centromeric vector, from an episomal multicopy expression vector or by introducing an (episomal) expression vector that comprises multiple copies of the gene.
- overexpression of the enzyme according to the invention is achieved with a (strong) constitutive promoter.
- the invention also relates to a nucleotide construct comprising one or more nucleotide sequence(s) selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 10.
- the nucleic acid construct may be a plasmid, for instance a low copy plasmid or a high copy plasmid.
- the eukaryotic cell according to the present invention may comprise a single, but preferably comprises multiple copies of the nucleotide sequence encoding a NAD(H) dependent fumarate reductase, for instance by multiple copies of a nucleotide construct.
- the nucleic acid construct may be maintained episomally and thus comprise a sequence for autonomous replication, such as an autosomal replication sequence.
- a suitable episomal nucleic acid construct may e.g. be based on the yeast 2 ⁇ or pKD1 plasmids ( Gleer et al., 1991, Biotechnology 9: 968-975 ), or the AMA plasmids ( Fierro et al., 1995, Curr Genet. 29:482-489 ).
- each nucleic acid construct may be integrated in one or more copies into the genome of the eukaryotic cell. Integration into the cell's genome may occur at random by non-homologous recombination but preferably, the nucleic acid construct may be integrated into the cell's genome by homologous recombination as is well known in the art.
- the nucleotide sequence encoding a NAD(H)-dependent fumarate reductase may be a heterologous or a homologous nucleotide sequence.
- the NADH-dependent fumarate reductase is a heterologous enzyme, which may be derived from any suitable origin, for instance bacteria, fungi, protozoa or plants.
- the cell according to the invention comprises hetereologous a NAD(H)-dependent fumarate reductase, preferably derived from a Trypanosoma sp, for instance a Trypanosoma brucei.
- nucleotide sequence encoding a NAD(H)-dependent fumarate reductase comprises a peroxisomal or mitochondrial targeting signal
- it may be essential to modify or delete a number of amino acids (and corresponding nucleotide sequences in the encoding nucleotide sequence) in order to prevent peroxisomal or mitochondrial targeting of the enzyme.
- the presence of a peroxisomal targeting signal may for instance be determined by the method disclosed by Schlüter et al, Nucleic acid Research 2007, 35, D815-D822 .
- the NAD(H)-dependent fumarate reductase lacks a peroxisomal or mitochondrial targeting signal for cytosolic activity of the enzyme upon expression of the encoding nucleotide sequence.
- the eukaryotic cell selected from the group consisting of a yeast and a filamentous fungus preferably belongs to one of the genera Saccharomyces, Aspergillus, Penicillium, Pichia, Kiuyveromyces, Yarrowia, Candida, Hansenula, Humicola, Rhizopus, Torulaspora, Trichosporon, Brettanomyces, Zygosaccharomyces, Pachysolen or Yamadazyma.
- the eukaryotic cell is a Saccharomyces cervisiae, Saccharomyces uvarum, Saccharomyces Bayanus, Aspergillus niger, Penicillium chrysogenum, Pichia stipidis, Kluyveromyces marxianus, K. lactis, K. thermotolerans, Yarrowia lipolytica, Candida sonorensis, C. glabrata, Hansenula polymorpha, Torulaspora delbrueckii, Brettanomyces bruxellensis, Rhizopus orizae or Zygosaccharomyces bailii.
- heterologous and/or homologous nucleotide sequences encoding i) an enzyme that catalyses the conversion of phosphoenolpyruvate or pyruvate to oxaloacetate; ii) a malate dehydrogenase which catalyses the conversion from OAA to malic acid; or iii) a fumarase, which catalyses the conversion of malic acid to fumaric acid.
- a eukaryotic cell may be transformed or genetically modified with any suitable nucleotide sequence catalyzing the reaction from a C3 to C4 carbon molecule, such as phosphoenolpyruvate (PEP, C3) to oxaloacetate (OAA, C4) and pyruvate (C3) to OAA or malic acid (C3).
- PEP phosphoenolpyruvate
- OAA oxaloacetate
- C3 pyruvate
- C3 pyruvate
- malic acid C3
- Suitable enzymes are PEP carboxykinase (EC 4.1.1.49, EC 4.1.1.38) and PEP carboxylase (EC 4.1.1.31) which catalyse the conversion of PEP to OAA; pyruvate carboxylase (EC 6.4.1.1.), that catalyses the reaction from pyruvate to OAA; or malic enzyme (EC 1.1.1.38), that catalyses the reaction from pyruvate to malic acid.
- a eukaryotic cell according to the present invention overexpresses a nucleotide sequence encoding a pyruvate carboxylase (PYC), preferably a pyruvate carboxylase that is active in the cytosol upon expression of the nucleotide sequence encoding a PYC, for instance a PYC comprising an amino acid sequence according to SEQ ID NO: 41.
- PYC pyruvate carboxylase
- an endogenous or homologous pyruvate carboxylase is overexpressed. Surprisingly, it was found that overexpressing an endogenous pyruvate carboxylase resulted in increased succinic acid production levels by the eukaryotic cell according to the present invention.
- a eukaryotic cell according to the present invention further comprises a nucleotide sequence encoding a heterologous PEP carboxykinase (EC 4.1.1.49) catalysing the reaction from phosphoenolpyruvate to oxaloacetate.
- a eukaryotic cell according to the present invention which further comprises a heterologous PEP carboxykinase produced an increased amount of succinic acid as compared to a eukaryotic cell that does not comprise the heterologous PEP carboxykinase.
- a PEP carboxykinase that is derived from bacteria, more preferably the enzyme having PEP carboxykinase activity is derived from Escherichia coli, Mannheimia sp., Actinobacillus sp., or Anaerobiospirillum sp ., more preferably Mannheimia succiniciproducens, Actinobacillus succinogenes, or Anaerobiospirillum succiniciproducens.
- the PEP carboxykinase is active in the cytosol upon expression of the nucleotide sequence encoding PEP carboxykinase since it was found that this resulted in an increase succinic acid production.
- a eukaryotic cell comprises a PEP carboxykinase which has at least 80, 85, 90, 95 or 99% sequence identity with SEQ ID NO: 14 or SEQ ID NO: 17, preferably a PEP carboxykinase comprising SEQ ID NO: 14 or SEQ ID NO: 17.
- a PEP carboxykinase which has at least 80, 85, 90, 95 or 99% sequence identity with SEQ ID NO: 14 or SEQ ID NO: 17, preferably a PEP carboxykinase comprising SEQ ID NO: 14 or SEQ ID NO: 17.
- a cell according to the present invention further comprises a nucleotide sequence encoding a malate dehydrogenase (MDH) which is active in the cytosol upon expression of the nucleotide sequence.
- MDH malate dehydrogenase
- a cytosolic MDH may be any suitable homologous or heterologous malate dehydrogenase.
- the MDH may be a S. cerevisiae MDH3 or S. cerevisiae MDH1.
- the MDH lacks a peroxisomal or mitochondrial targeting signal in order to localize the enzyme in the cytosol.
- the MDH is S. cerevisiae MDH2 which has been modified such that it is not inactivated in the presence of glucose and is active in the cytosol.
- Mdh2p deleted for the first 12 amino-terminal amino acids is less-susceptible for glucose-induced degradation ( Minard and McAlister-Henn, J. Biol Chem. 1992 Aug 25;267(24):17458-64 ).
- a eukaryotic cell comprises a nucleotide sequence encoding a malate dehydrogenase that has at least 70%, preferably at least 75, 80, 85, 90, 92, 94, 95, 96, 97, 98, 99% sequence identity with the amino acid sequence of SEQ ID NO: 19 or SEQ ID NO: 21.
- the malate dehydrogenase comprises SEQ ID NO: 19 or SEQ ID NO: 21.
- the activity of malate dehydrogenase is increased by overexpressing the encoding nucleotide sequence by known methods in the art.
- a eukaryotic cell according to the present invention further comprises a nucleotide sequence encoding an enzyme that catalyses the conversion of malic acid to fumaric acid, which may be a heterologous or homologous enzyme, for instance a fumarase (FUM).
- a nucleotide sequence encoding an heterologous enzyme that catalyses the conversion of malic acid to fumaric acid may be derived from any suitable origin, preferably from microbial origin, preferably from a yeast, for instance Saccharomyces cerevisiae or a filamentous fungus, for instance Rhizopus oryzae.
- a eukaryotic cell according to the present invention comprises a nucleotide sequence encoding a fumarase that has at least 70%, preferably at least 75, 80, 85, 90, 92, 94, 95, 96, 97, 98, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 23.
- the fumarase comprises SEQ ID NO: 23.
- the enzyme having fumarase activity is active in the cytosol upon expression of the nucleotide sequence encoding the enzyme having fumarase activity. Surprisingly, it was found that a eukaryotic cell further comprising an enzyme having fumarase activity as described herein produced an increased amount of succinic acid.
- a eukaryotic cell comprises a nucleotide sequence encoding a dicarboxylic acid transporter protein, preferably a malic acid transporter protein (MAE).
- a dicarboxylic acid transporter protein may be a homologous or heterologous protein.
- the dicarboxylic acid transporter protein is a heterologous protein.
- a dicarboxylic acid transporter protein may be derived from any suitable organism, preferably from Schizosaccharomyces pombe.
- a dicarboxylic acid transporter protein is a malic acid transporter protein (MAE) which has at least 80, 85, 90, 95 or 99% sequence identity with SEQ ID NO: 36.
- the MAE comprises SEQ ID NO: 36.
- a eukaryotic cell according to the present invention further comprising a dicarboxylic acid transporter, such as a malic acid transporter as described herein produced an increased amount of succinic acid as compared to a eukaryote cell not comprising a dicarboxylic acid transporter protein.
- a eukaryotic cell is a yeast comprising nucleotide sequences encoding a NAD(H)-dependent fumarate reductase, a malate dehydrogenase, a heterologous fumarase, a heterologous PEP carboxykinase and a heterologous dicarboxylic acid transporter and overexpresses a pyruvate carboxylase (PYC), as described, including the preferred embodiments, herein above.
- PYC pyruvate carboxylase
- a yeast of the invention comprising the nucleotide sequences encoding the enzymes as described herein produced an increased amount of succinic acid as compared to a yeast comprising either of the nucleotide sequences alone.
- a eukaryotic cell according to the present invention comprises reduced activity of enzymes that convert NAD(H) to NAD + compared to the activity of these enzymes in a wild-type cell.
- the cell according to the present invention is a cell wherein at least one gene encoding alcohol dehydrogenase is not functional.
- An alcohol dehydrogenase gene that is not functional is used herein to describe a eukaryotic cell which comprises a reduced alcohol dehydrogenase activity compared to a cell wherein all genes encoding an alcohol dehydrogenase are functional.
- a gene may become not functional by known methods in the art, for instance by mutation, disruption, or deletion, for instance by the method disclosed by Gueldener et. al. 2002, Nucleic Acids Research, Vol. 30, No. 6, e23 .
- a eukaryotic cell is a yeast cell such as Saccharomyces cerevisiae, wherein one or more genes adh1 and/or adh2, encoding alcohol dehydrogenase are inactivated.
- the cell according to the present invention further comprises at least one gene encoding glycerol-3-phosphate dehydrogenase which is not functional.
- a glycerol-3-phosphate dehydrogenase gene that is not functional is used herein to describe a eukaryotic cell, which comprises a reduced glycerol-3-phosphate dehydrogenase activity, for instance by mutation, disruption, or deletion of the gene encoding glycerol-3-phosphate dehydrogenase, resulting in a decreased formation of glycerol as compared to the wild-type cell.
- the eukaryotic cell comprising reduced alcohol dehydrogenase activity and/or glycerol-3-phosphate dehydrogenase activity and a NAD(H)-dependent fumarase resulted in an increased production of succinic acid as compared to a cell wherein one or more gene(s) encoding alcohol dehydrogenase and/or glycerol-3-phosphate dehydrogenase are not inactivated.
- the present invention also relates to a process for the production of succinic acid comprising fermenting a eukaryotic cell comprising at least one gene encoding alcohol dehydrogenase is not functional and / or at least one gene encoding glycerol-3-phosphate dehydrogenase which is not functional.
- the recombinant eukaryotic cell according to the present invention comprises at least one gene encoding succinate dehydrogenase that is not functional.
- a succinate dehydrogenase that is not functional is used herein to describe a eukaryotic cell, which comprises a reduced succinate dehydrogenase activity by mutation, disruption, or deletion, of at least one gene encoding succinate dehydrogenase resulting in a increased formation of succinic acid as compared to the wild-type cell.
- a eukaryotic cell comprising a gene encoding succinate dehydrogenase that is not functional may for instance be Aspergillus niger, preferably an Aspergillus niger, wherein one or more genes encoding succinate dehydrogenase, such as sdhA and sdhB is/are not functional, for instance by deletion of these genes.
- a eukaryotic cell according to the invention is a yeast, preferably Saccharomyces cerevisiae, preferably a Saccharomyces cerevisiae comprising one or more of the nucleotide sequences selected from SEQ ID NO: 9 and SEQ ID NO: 10.
- a eukaryotic cell according to the present invention may also be a filamentous fungus, preferably A. niger, preferably A. niger comprising one or more nucleotide sequences selected from SEQ ID NO: 7 and SEQ ID NO: 8.
- a eukaryotic cell according to the present invention comprising any one of the genetic modifications described herein is capable of producing at least 0.3, 0.5, 0.7, g / L succinic acid, preferably at least 1 g / L succinic acid, preferably at least 1.5 preferably at least 2, or 2.5, 4.5 preferably at least 8, 10, 15, or 20 g / L succinic acid but usually below 200 or below 150 g / L.
- a preferred eukaryotic cell according to the present invention may be able to grow on any suitable carbon source known in the art and convert it to succinic acid.
- the eukaryotic cell may be able to convert directly plant biomass, celluloses, hemicelluloses, pectines, rhamnose, galactose, fucose, maltose, maltodextrines, ribose, ribulose, or starch, starch derivatives, sucrose, lactose and glycerol.
- a preferred host organism expresses enzymes such as cellulases (endocellulases and exocellulases) and hemicellulases (e.g.
- the cell is able to convert a carbon source selected from the group consisting of glucose, fructose, galactose, xylose, arabinose, sucrose, raffinose, lactose and glycerol.
- the present invention relates to a process for the preparation of succinic acid, comprising fermenting the eukaryotic cell according to the present invention, wherein succinic acid is prepared.
- the succinic acid that is prepared in the process according to the present invention is further converted into a desirable product.
- a desirable product may for instance be a polymer, such as polybutylene succinic acid (PBS), a deicing agent, or a surfactant.
- the process according to the present invention may be run under aerobic and anaerobic conditions.
- the process is carried out under anaerobic conditions or under micro-aerophilic or oxygen limited conditions.
- An anaerobic fermentation process is herein defined as a fermentation process run in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than 5, 2.5 or 1 mmol/L/h, and wherein organic molecules serve as both electron donor and electron acceptors.
- An oxygen-limited fermentation process is a process in which the oxygen consumption is limited by the oxygen transfer from the gas to the liquid.
- the degree of oxygen limitation is determined by the amount and composition of the ingoing gasflow as well as the actual mixing/mass transfer properties of the fermentation equipment used.
- the rate of oxygen consumption is at least 5.5, more preferably at least 6 and even more preferably at least 7 mmol/L/h.
- the process for the production of succinic acid according to the present invention may be carried out at any suitable pH between 1 and 9.
- the pH in the fermentation broth is between 2 and 7, preferably between 3 and 5. It was found advantageous to be able to carry out the process according to the present invention at a low pH, since this prevents bacterial contamination. In addition, since the pH drops during succinic acid production, a lower amount of titrant may be needed to keep the pH at a desired level.
- a suitable temperature at which the process according to the present invention may be carried out is between 5 and 60°C, preferably between 10 and 50°C, more preferably between 15 and 35°C, more preferably between 18°C and 30°C.
- the skilled man in the art knows which optimal temperatures are suitable for fermenting a specific eukaryotic cell.
- succinic acid is recovered from the fermentation broth by a suitable method known in the art, for instance by crystallisation and ammonium precipitation.
- the succinic acid that is prepared in the process according to the present invention is further converted into a pharmaceutical, cosmetic, food, feed, or chemical product.
- Succinic acid may be further converted into a polymer, such as polybutylene succinate (PBS) or other suitable polymers derived therefrom.
- PBS polybutylene succinate
- the present invention also relates to a fermentation broth comprising a succinic acid wherein the fermentation broth is obtainable by a process according to the present invention.
- the invention relates to a process for the production of succinic acid by a yeast or a filamentous fungus as succinic acid producer, whereby fumarate reductase from Trypanosoma brucei is used to increase succinic acid production, wherein preferably the fumarate reductase is active in the cytosol.
- Standard genetic techniques such as overexpression of enzymes in the host cells, genetic modification of host cells, or hybridisation techniques, are known methods in the art, such as described in Sambrook and Russel (2001) "Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press , or F. Ausubel et al, eds., “Current protocols in molecular biology”, Green Publishing and Wiley Interscience, New York (1987 ). Methods for transformation, genetic modification etc of fungal host cells are known from e.g.
- EP-A-0 635 574 WO 98/46772 , WO 99/60102 and WO 00/37671 , WO90/14423 , EP-A-0481008 , EP-A-0635 574 and US 6,265,186 .
- Mitochondrial fumarate reductase m1 [E.C. 1.3.1.6], GenBank accession number 60460035, from Trypanosoma brucei was analysed for the presence of signal sequences using SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/) Bendtsen, J. et al. (2004) Mol. Biol., 340:783-795 and TargetP 1.1 (http://www.cbs.dtu.dk/services/TargetP/) Emanuelsson, O. et al. (2007) Nature Protocols 2, 953-971 . A putative mitochondrial targeting sequence in the N-terminal half of the protein was identified, including a possible cleavage site between pos. 25 and 26 (D-S).
- SEQ ID NO: 3 was subjected to the codon-pair method as disclosed in WO2008/000632 for A. niger.
- the resulting sequence SEQ ID NO: 7 was put behind the constitutive GPDA promoter sequence SEQ ID NO: 11, wherein the last 10 nucleotide sequences were replaced with optimal Kozak sequence CACCGTAAA. Convenient restriction sites were added.
- the stop codon TAA in SEQ: ID NO: 7 was modified to TAAA.
- the resulting sequence was synthesised at Sloning (Puchheim, Germany).
- the fragment was Sna BI, Sfi I cloned in the A. niger expression vector pGBTOP11 ( Figure 1 ) using appropriate restriction sites.
- the resulting plasmid comprising FRDm1 was named pGBTOPAn1 ( Figure 5 ).
- glycosomal fumarate reductase [E.C. 1.3.1.6], GenBank accession number 23928422, from Trypanosoma brucei was analysed for peroxisomal targeting in filamentous fungi using the PTS1 predictor httg:/imendel.imp.ac.at/mendeljsp/sat/pts1/PRS1predictor.jsp with the fungi-specific prediction function.
- the C-terminal amino acids at position 1140-1142 (SKI) were removed from the protein SEQ ID NO: 4 (corresponding to nucleotide sequence SEQ ID NO: 5), resulting in SEQ ID NO: 6.
- SEQ ID NO: 6 was subjected to the codon-pair method as disclosed in PCT/EP2007/05594 for A. niger.
- the stop codon TAA in SEQ ID NO: 8 was modified to TAAA.
- the resulting sequence SEQ ID NO: 8 was put behind the constitutive GPDA promoter sequence SEQ ID NO: 11, and convenient restriction sites were added.
- the resulting sequence was synthesised at Sloning (Puchheim, Germany).
- the fragment was Sna BI, Sfi I cloned in the A. niger expression vector pGBTOP11 ( Figure 1 ) using appropriate restriction sites.
- A. niger WT-1 This A. niger strain is CBS513.88 comprising deletions of the genes encoding glucoamylase ( gla A), fungal amylase and acid amylase.
- A. niger WT 1 was constructed by using the "MARKER-GENE FREE" approach as described in EP 0 635 574 B1 .
- HPLC is performed for the determination of organic acids and sugars in different kinds of samples.
- the principle of the separation on a Phenomenex Rezex-RHM-Monosaccharide column is based on size exclusion, ion-exclusion and ion-exchange using reversed phase mechanisms. Detection takes place by differential refractive index and ultra violet detectors.
- Mitochondrial fumarate reductase m1 [E.C. 1.3.1.6], GenBank accession number 60460035, from Trypanosoma brucei was analysed for the presence of signal sequences and codon optimized as described in section 1.1 for expression in S. cerevisiae.
- the resulting sequence SEQ ID NO: 9 was put behind the constitutive TDH3 promoter sequence SEQ ID NO: 12 and before the TDH3 terminator sequence SEQ ID NO: 13, and convenient restriction sites were added.
- the stop codon TGA in SEQ ID NO: 9 was modified to TAAG.
- the resulting sequence was synthesised at Sloning (Puchheim, Germany).
- the expression construct pGBS414SUS-07 was created after a Bam HI/ Not I restriction of the S. cerevisiae expression vector pRS414 ( Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27 ) and subsequently ligating in this vector a Bam HI/ Not I restriction fragment consisting of the fumarate reductase synthetic gene construct ( Figure 2 ).
- the ligation mix is used for transformation of E. coli DH10B (Invitrogen) resulting in the yeast expression construct pGBS414SUS-07 ( Figure 2 ).
- glycosomal fumarate reductase (FRDg) [E.C. 1.3.1.6], GenBank accession number 23928422, from Trypanosoma brucei was analysed for peroxisomal targeting and codon optimisation was applied as described in section 1.1 for expression in S. cerevisiae.
- the resulting sequence SEQ ID NO: 10 was put behind the constitutive TDH3 promoter sequence SEQ ID NO: 12 and before the TDH3 terminator sequence SEQ ID NO: 13, and convenient restriction sites were added.
- the stop codon TGA in SEQ ID NO: 10 was modified to TAAG.
- the resulting sequence was synthesised at Sloning (Puchheim, Germany).
- the expression construct pGBS414SUS-08 was created after a Bam HI/ Not I restriction of the S. cerevisiae expression vector pRS414 ( Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27 ) and subsequently ligating in this vector a Bam HI/ Not I restriction fragment consisting of the fumarate reductase synthetic gene construct ( Figure 3 ).
- the ligation mix is used for transformation of E. coli DH10B (Invitrogen) resulting in the yeast expression construct pGBS414SUS-08 ( Figure 3 ).
- the constructs pGBS414SUS-07 and pGBS414SUS-08 are independently transformed into S. cerevisiae strains CEN.PK113-6B ( MATA ura3-52 leu2-112 trp1-289 ), RWB066 ( MATA ura3-52 leu2-112 trp1-289 adh1::lox adh2::Kanlox ) and RWB064 ( MATA ura3-52 leu2-112 trp1-289 adh1::lox adh2::lox gpd1::Kanlox). Transformation mixtures are plated on Yeast Nitrogen Base (YNB) w/o AA (Difco) + 2% glucose supplemented with appropriate amino acids.
- YNB Yeast Nitrogen Base
- Transformants are inoculated in Verduyn medium comprising glucose supplemented with appropriate amino acids ( Verduyn et al., 1992, Yeast. Jul;8(7):501-17 ) and grown under aerobic, anaerobic and oxygen-limited conditions in shake flasks.
- the medium for anaerobic cultivation is supplemented with 0.01 g/l ergosterol and 0.42 g/l Tween 80 dissolved in ethanol ( Andreasen and Stier, 1953, J. cell. Physiol, 41, 23-36 ; Andreasen and Stier, 1954, J. Cell. Physiol, 43: 271-281 ). All yeast cultures are grown at 30°C in a shaking incubator at 250-280 rpm. At different incubation times, aliquots of the cultures are removed, centrifuged and the medium is analysed by HPLC for formation of oxalic acid, malic acid, fumaric acid and succinic acid as described in section 1.4.
- Example 2A.1 mitochondrial fumarate reductase from Trypanosoma brucei (FRDm, SEQ ID NO: 9) was ligated in a S. cerevisiae expression vector pRS416 ( Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27 ). The ligation mix was used for transformation of E. coli TOP10 cells (Invitrogen) resulting in the yeast expression constructs and pGBS416FRD-1 ( Figure 7 ).
- glycosomal fumarate reductase (FRDg, SEQ ID NO: 10) from Trypanosoma brucei was ligated in an S. cerevisiae expression vector pRS416.
- the ligation mix was used for transformation of E. coli TOP10 cells (Invitrogen) resulting in the yeast expression construct pGBS416FRE-1 ( Figure 8 ).
- the constructs pGBS416FRD-1 and pGBS416FRE-1 were independently transformed into S. cerevisiae strain CEN.PK113-5D (MATA ura3-52). As negative control, empty vector pRS416 was transformed into strain CEN.PK 113-5D. Transformation mixtures were plated on Yeast Nitrogen Base (YNB) w/o AA (Difco) + 2% glucose.
- YNB Yeast Nitrogen Base
- This SEQ ID NO: 16 containing stop codon TAAG was put behind the constitutive TDH1 promoter sequence SEQ ID NO: 25 and before the TDH1 terminator sequence SEQ ID NO: 26, and convenient restriction sites were added.
- the resulting sequence SEQ ID NO: 29 was synthesised at Sloning (Puchheim, Germany).
- phosphoenolpyruvate carboxykinase [E.C. 4.1.1.49], GenBank accession number 52426348, from Mannheimia succiniciproducens was analysed for the presence of signal sequences as described in Schlüter et al., (2007) NAR, 35, D815-D822 .
- the sequence as shown in SEQ ID NO: 17 required no modifications.
- SEQ ID NO: 17 was subjected to the codon-pair method as disclosed in WO2008/000632 for S. cerevisiae.
- the stop codon TAA in the resulting sequence SEQ ID NO: 18 was modified to TAAG.
- SEQ ID NO: 18 containing stop codon TAAG was put behind the constitutive TDH1 promoter sequence SEQ ID NO: 25 and before the TDH1 terminator sequence SEQ ID NO: 26. Convenient restriction sites were added. The resulting synthetic construct (SEQ ID NO: 30) was synthesised at Sloning (Puchheim, Germany).
- Cytoplasmic malate dehydrogenase [E.C. 1.1.1.37], GenBank accession number 171915, is regulated by carbon catabolite repression: transcription of MDH2 is repressed and Mdh2p is degraded upon addition of glucose to glucose-starved cells. Mdh2p deleted for the 12 amino-terminal amino acids is less-susceptible for glucose-induced degradation ( Minard and McAlister-Henn, J Biol Chem. 1992 Aug 25;267(24):17458-64 ).
- SEQ ID NO: 19 was subjected to the codon-pair method as disclosed in WO2008/000632 for S. cerevisiae.
- the stop codon TAA in the resulting in SEQ ID NO: 20, was modified to TAAG.
- SEQ ID NO: 20 containing a modified stop codon TAAG, encoding delta12NMDH2 was put behind the constitutive TDH3 promoter sequence SEQ ID NO: 12 and before the TDH3 terminator sequence SEQ ID NO: 13, and convenient restriction sites were added.
- the resulting synthetic construct (SEQ ID NO: 31) was synthesised at Sloning (Puchheim, Germany).
- Peroxisomal malate dehydrogenase [E.C. 1.1.1.37], GenBank accession number 1431095, was analysed for peroxisomal targeting in filamentous fungi using the PTS1 predictor http://mendel.imp.ac.at/mendeljsp/sat/pts1/PTS1predictor.jsp with the fungi-specific prediction function.
- the C-terminal amino acids at position 341-343 (SKL) were removed from protein MDH3 resulting in SEQ ID NO: 21.
- SEQ ID NO: 21 was subjected to the codon-pair method as disclosed in WO2008/000632 for S. cerevisiae.
- Fumarase [E.C. 4.2.1.2], GenBank accession number 469103, from Rhizopus oryzae (FumR) was analysed for the presence of signal sequences using SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/) Bendtsen, J. et al. (2004) Mol. Biol., 340:783-795 and TargetP 1.1 (http://www.cbs.dtu.dk/services/TargetP/) Emanuelsson, O. et al. (2007) Nature Protocols 2, 953-971 . A putative mitochondrial targeting sequence in the first 23 amino acid of the protein was identified. To avoid potential targeting to mitochondria in S.
- SEQ ID NO: 23 was subjected to the codon-pair method as disclosed in WO2008/00063 for S. cerevisiae resulting in SEQ ID NO: 24.
- the stop codon TAA in SEQ ID NO: 24 was modified to TAAG.
- SEQ ID NO: 24 containing TAAG as stop codon was synthesized behind the constitutive TDH1 promoter sequence SEQ ID NO: 25 and before the TDH1 terminator sequence SEQ ID NO: 26 and convenient restriction sites were added.
- the resulting synthetic construct SEQ ID NO: 33 was synthesised at Sloning (Puchheim, Germany).
- the expression constructs pGBS414PPK-1 ( Figure 9 ), pGBS414PPK-2 ( Figure 10 ) and pGBS414PPK-3 ( Figure 11 ) were created after a Bam HI/ Not I restriction of the S. cerevisiae expression vector pRS414 ( Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27 ) and subsequently ligating in this vector a Bam HI/ Not I restriction fragment consisting of the phosphoenolpyruvate carboxykinase (origin Actinobacillus succinogenes ) synthetic gene construct (SEQ ID NO: 29). The ligation mix was used for transformation of E.
- an Asc I/ Not I restriction fragment consisting of glycosomal fumarate reductase from T. brucei (FRDg) synthetic gene construct (SEQ ID NO: 35) was ligated into the restricted pGBS414PPK-1 vector.
- the ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS414PPK-3 ( Figure 11 ).
- the expression constructs pGBS414PEK-1 ( Figure 12 ), pGBS414PEK-2 ( Figure 13 ) and pGBS414PEK-3 ( Figure 14 ) were created after a Bam HI/ Not I restriction of the S. cerevisiae expression vector pRS414 ( Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27 ) and subsequently ligating in this vector a Bam HI/ Not I restriction fragment consisting of the phosphoenolpyruvate carboxykinase (origin Mannheimia succiniciproducens ) synthetic gene construct (SEQ ID NO: 30). The ligation mix was used for transformation of E.
- the expression constructs pGBS415FUM-2 ( Figure 15 ) and pGBS415FUM-3 ( Figure 16 ) were created after a Bam HI/ Not I restriction of the S. cerevisiae expression vector pRS415 ( Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27 ) and subsequently ligating in this vector a Bam HI/ Not I restriction fragment consisting of the fumarase (origin Rhizopus oryzae) synthetic gene construct (SEQ ID NO: 33).
- the ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS415FUM-1.
- pGBK415FUM-1 was restricted with AscI and NotI.
- an Asc I/ Not I restriction fragment consisting of cytoplasmic malate dehydrogenase from S. cerevisiae (delta12N MDH2) synthetic gene construct (SEQ ID NO: 31) was ligated into the restricted pGBS415FUM-1 vector. The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS415FUM-2 ( Figure 15 ).
- an Asc I/ Not I restriction fragment consisting of peroxisomal malate dehydrogenase from S.
- MDH3 cerevisiae ( MDH3 ) synthetic gene construct (SEQ ID NO: 32) was ligated into the restricted pGBS415FUM-1 vector.
- the ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS415FUM-3 ( Figure 16 ).
- Transformants were inoculated in 20 ml pre-culture medium consisting of Verduyn medium (Verduyn et al., 1992, Yeast. Jul;B(7):501-17) comprising 2% galactose (w/v) and grown under aerobic conditions in 100 ml shake flasks in a shaking incubator at 30°C at 250 rpm. After 72 hours, the culture was centrifuged for 5 minutes at 4750 rpm. 1 ml supernatant was used to measure succinic acid levels by HPLC as described in section 1.4. The remaining supernatant was decanted and the pellet (cells) was resuspended in 1 ml production medium.
- the production medium consisted of Verduyn medium with 10 % galactose (w/v) and 1% CaCO3 (w/v).
- the resuspended cells were inoculated in 50 ml production medium in 100 ml shake flasks and grown in a shaking incubator at 30°C at 100 rpm. At various time points, 1 ml sample was taken from the culture succinic acid levels were measured by HPLC as described in section 1.4 ( Figure 17 ).
- glycosomal fumarate reductase from T. brucei resulted in an even higher increase in succinic acid production levels; overexpression of PCKa, MDH3, FUMR and FRDg resulted in production of 3.9 g/L succinic acid, whereas overexexpression of PCKm, MDH3, FUMR and FRDg resulted in slightly lower production of 3.6 g/L succinic acid.
- FRDg glycosomal fumarate reductase
- SEQ ID NO: 37 Malate permease, GenBank accession number 119368831, from Schizosaccharomyces pombe (SEQ ID NO: 36) was subjected to the codon-pair method as disclosed in WO2008/000632 for S. cerevisiae resulting in SEQ ID NO: 37.
- the stop codon TAA in SEQ ID NO: 37 was modified to TAAG.
- SEQ ID NO: 37 containing TAAG as stop codon was put behind the constitutive ENO1 promoter sequence SEQ ID NO: 38 and before the ENO1 terminator sequence SEQ ID NO: 39, and convenient restriction sites were added.
- T at position 596 (-5) was changed to A in order to obtain a better Kozak sequence.
- the resulting sequence SEQ ID NO: 40 was synthesised at Sloning (Puchheim, Germany):
- the expression constructs pGBS416MAE-1 ( Figure 18 ) was created after a Bam HI/ Not I restriction of the S. cerevisiae expression vector pRS416 ( Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27 ) and subsequently ligating in this vector a Bam HI/ Not I restriction fragment consisting of the Schizosaccharomyces pombe malate transporter synthetic gene construct (SEQ ID NO: 40). The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS416MAE-1.
- Plasmids pGBS414PEK-2, pGBS415FUM-2 and pGBS416MAE-1 (described under 2C.2.) were transformed into S. cerevisiae strain CEN.PK113-6B ( MATA ura3-52 leu2-112 trp1-289) to create strain SUC-194, overexpressing PCKm, delta12NMDH2, FUMR, FRDm1 and SpMAE1. All genes were codon pair optimized for expression in S. cerevisiae.
- the expression vectors were transformed into yeast by electroporation.
- the transformation mixtures were plated on Yeast Nitrogen Base (YNB) w/o AA (Difco) + 2% glucose.
- YNB Yeast Nitrogen Base
- AA Difco
- strains SUC-101 is described in Table 2.
- Table 3 Yeast strains constructed for Example 2D.
- strains transformed with empty vectors produced up to 0.3 g/L succinic acid. Additional overexpression of SpMAE1 in strain SUC-194, overexpressing PCKm, delta12NMDH2, FUMR and FRDm1 resulted in increased succinic acid production levels to 4.6 g/L, whereas strain SUC-132, overexpressing PCKm, delta12NMDH2, FUMR and FRDm1 resulted in production of 2.7 g/L succinic acid.
- Plasmids pGBS414PPK-3, pGBS415FUM-3 and pGBS416MAE-1 (described under 2C.2.) were transformed into S. cerevisiae strain RWB064 ( MATA ura3-52 leu2-112 trp1-289 adh1::lox adh2::lox gpd1::Kanlox ) to create strain SUC-201, overexpressing PCKa, MDH3, FUMR, FRDg and SpMAE1. All genes were codon pair optimized for expression in S. cerevisiae.
- Table 4 Yeast strains constructed for Example 2E.
- Strain SUC-103 transformed with empty vectors (control strain) produced 0.9 g/L succinic acid after growth for 10 days in production medium ( Figure 20 ).
- Overexpression of PCKa, MDH3, FUMR and FRDg in strain RWB064 resulted in increased succinic acid production levels to 2.5 g/L (strain SUC-201, Figure 20 ).
- Additional overexpression of SpMAE1 besides PCKa, MDH3, FUMR and FRDg in strain RWB064 resulted in a further increase of succinic acid production levels to 11.9 g/L (strain SUC-200, Figure 20 ).
- cerevisiae strain CEN.PK113-5D (MATA ura3-52) was used as template to amplify the PYC2 coding sequence (SEQ ID NO: 42), using primers P1 (SEQ ID NO: 43) and P2 (SEQ ID NO: 44), and the Phusion DNA polymerase (Finnzymes, Finland) according to manufacturer's instructions. Convenient restriction sites were included in the primers for further cloning purposes.
- the expression construct pGBS426PYC-2 ( Figure 21 ) was created after a Spel/Xhol restriction of the S. cerevisiae expression vector p426GPD ( Mumberg et al., Gene. 1995 Apr 14;156(1):119-22 ) and subsequently ligating in this vector a Spel/Xhol restriction fragment consisting of the amplified PYC2 nucleotide sequence (SEQ ID NO: 42).
- the ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS426PYC-2 ( Figure 21 ). Construction of expression vectors pGBS414PPK-3 and pGBS415FUM-3 is described under 2C.2.
- Expression construct pGBS414FRE-1 was created after a Bam HI/ Not I restriction of the S. cerevisiae expression vector pRS414 ( Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27 ) and subsequently ligating in this vector a Bam HI/ Not I restriction fragment consisting of the glycosomal fumarate reductase (origin Trypanosoma brucei ) synthetic gene construct (SEQ ID NO: 35). The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS414FRE-1 ( Figure 22 ).
- Strains SUC-226, SUC-227, SUC-228 and SUC-230 were obtained by transformation of different combinations of the plasmids pGBS414FRE-1, pGBS414PPK-3, pGBS415FUM-1, pGBS426PYC-2 and p426GPD into stain CEN.PK113-6B ( MATA ura3-52 leu2-112 trp1-289 ), as depicted in Table 5.
- Table 5 Yeast strains constructed for Example 2F.
- strain SUC-230 overexpressing MDH3, FUMR and FRDg, produced up to 3.0 g/L succinic acid.
- Additional overexpression of PCKa increased succinic acid production up to 3.4 g/L (strain SUC-226)
- additional overexpression of PYC2 increased succinic acid production up to 3.7 g/L (strain SUC-228).
- overexpression of both PCKa and PYC2 resultsed in 1.5 increase of succinic acid production levels up to 5.0 g/L, as compared to the effect of PCK and PYC alone.
- Genomic DNA of Aspergillus niger strain CBS513.88 was sequenced and analyzed. Two genes with translated proteins annotated as homologues to succinate dehydrogenase proteins were identified and named sdhA and sdhB respectively. Sequences of the sdhA (An16g07150) and sdhB (An02g12770) loci are available on genbank with accession numbers 145253004 and 145234071 respectively. Gene replacement vectors for sdhA and sdhB were designed according to known principles and constructed according to routine cloning procedures (see figure 6 ).
- the vectors comprise approximately 1000 bp flanking regions of the sdh ORFs for homologous recombination at the predestined genomic loci.
- they contain the A. nidulans bi-directional amd S selection marker driven by the gpdA promoter, in-between direct repeats.
- the general design of these deletion vectors were previously described in EP635574B and WO 98/46772 .
- Linear DNA of deletion vector pDEL-SDHA ( figure 4 ) was isolated and used to transform Aspergillus niger CBS513.88 as described in: Biotechnology of Filamentous fungi: Technology and Products. (1992) Reed Publishing (USA); Chapter 6: Transformation p. 113 to 156 .
- This linear DNA can integrate into the genome at the sdhA locus, thus substituting the sdhA gene by the amd S gene as depicted in figure 6 .
- Transformants were selected on acetamide media and colony purified according to standard procedures as described in EP635574B . Spores were plated on fluoro-acetamide media to select strains, which lost the amd S marker.
- Strain dSDHA was selected as a representative strain with the sdhA gene inactivated.
- the succinic acid production of dSDHA was determined in microtiterplates as described in Example 4.
- A. niger strain dSDHA of example 3.2. was transformed with the expression construct pGBTOPAn1 ( Figure 5 ) comprising truncated mitochondrial fumarate reductase m1 (FRDm1, SEQ ID NO:7) as described in Example 1.1.
- E. coli DNA was removed by NotI digestion.
- A. niger transformants were picked using Qpix and transferred onto MTP's containing Aspergillus selective media. After 7 days incubation at 30 degrees Celsius the biomass was transferred to microtiter plates (MTP's) containing PDA by hand or colony picker. After 7 days incubation at 30 degrees Celsius, the biomass was sporulated.
- MTP's microtiter plates
- Table 6 clearly shows an increased production of succinic acid by A. niger that comprises mitochondrial fumarate reductase from T. brucei
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Fuel Cell (AREA)
Abstract
Description
- The present invention relates to a recombinant eukaryotic cell comprising a nucleotide sequence encoding a fumarate reductase and a process for the production of succinic acid wherein the recombinant eukaryotic cell is used.
- Succinic acid is a potential precursor for numerous chemicals. For example, succinic acid can be converted into 1,4-butanediol (BDO), tetrahydrofuran, and gamma-butyrolactone. Another product derived from succinic acid is a polyester polymer which is made by linking succinic acid and BDO.
- Succinic acid is predominantly produced through petrochemical processes by hydrogenation of butane. These processes are considered harmful for the environment and costly. The fermentative production of succinic acid may be an attractive alternative process for the production of succinic acid, wherein renewable feedstock as a carbon source may be used.
- A number of different bacteria such as Escherichia coli, and the rumen bacteria Actinobacillus, Anaerobiospirillum, Bacteroides, Mannheimia, or Succinimonas, sp. are known to produce succinic acid. Metabolic engineering of these bacterial strains have improved the succinic acid yield and/or productivity, or reduced the by-product formation.
EP1,672,077 for instance discloses a Brevibacterium flavum genetically modified with fumarate reductase from Escherichia coli, which increased the succinic acid yield. -
WO2007/061590 discloses a pyruvate decarboxylase negative yeast for the production of malic acid and/or succinic acid which is transformed with a pyruvate carboxylase enzyme or a phosphoenolpyruvate carboxylase, a malate dehydrogenase enzyme, and a malic acid transporter protein (MAE). - Despite the improvements that have been made in the fermentative production of succinic acid, there remains a need for improved microorganisms for the fermentative production of succinic acid.
- The aim of the present invention is an alternative microorganism for the production of succinic acid.
- The aim is achieved according to the invention with a recombinant eukaryotic cell selected from the group consisting of a yeast and a filamentous fungus comprising a nucleotide sequence encoding NAD(H)-dependent fumarate reductase that catalyses the conversion of fumaric acid to succinic acid.
- Surprisingly it was found that the recombinant eukaryotic cell according to the present invention produces an increased amount of succinic acid compared to the amount of succinic acid produced by a wild-type eukaryotic cell. Preferably, a eukaryotic cell according to the present invention produces at least 1.2, preferably at least 1.5, preferably at least 2 times more succinic acid than a wild-type eukaryotic cell which does not comprise the nucleotide sequence encoding NAD(H)-dependent fumarate reductase.
- As used herein, a recombinant eukaryotic cell according to the present invention is defined as a cell which contains, or is transformed or genetically modified with a nucleotide sequence or polypeptide that does not naturally occur in the eukaryotic cell, or it contains additional copy or copies of an endogenous nucleic acid sequence. A wild-type eukaryotic cell is herein defined as the parental cell of the recombinant cell.
- The nucleotide sequence encoding a NAD(H)-dependent fumarate reductase that catalyses the conversion of fumaric acid to succinic acid may be a heterologous or homologous nucleotide sequence, or encodes a heterologous or homologous NAD(H)-dependent fumarate reductase, which may have been further genetically modified by mutation, disruption or deletion. Recombinant DNA techniques are well known in the art such as in Sambrook and Russel (2001) "Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory Press.
- The term "homologous" when used to indicate the relation between a given (recombinant) nucleic acid or polypeptide molecule and a given host organism or host cell, is understood to mean that in nature the nucleic acid or polypeptide molecule is produced by a host cell or organisms of the same species, preferably of the same variety or strain.
- The term "heterologous" when used with respect to a nucleic acid (DNA or RNA) or protein refers to a nucleic acid or protein that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differ from that in which it is found in nature. Heterologous nucleic acids or proteins are not endogenous to the cell into which it is introduced, but have been obtained from another cell or synthetically or recombinantly produced.
- A NAD(H)-dependent fumarate reductase according to the present invention uses NAD(H) as a cofactor, whereas most eukaryotic cells comprise a FADH2 -dependent fumarate reductase, wherein FADH2 is the cofactor. It was found advantageous that the eukaryotic cell comprises a nucleotide sequence encoding a NAD(H)-dependent fumarate reductase, since the NAD(H)-dependent fumarate reductase provides the cell with further options to oxidise NAD(H) to NAD+ and influence the redox balance in the cell.
- Preferably, the cell expresses a nucleotide sequence encoding an enzyme that catalyses the formation of succinic acid, wherein the nucleotide sequence preferably encodes a NAD(H)-dependent fumarate reductase, comprising an amino acid sequence that has at least 40%, preferably at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 97, 98, 99% sequence identity with the amino acid sequence of SEQ ID NO: 1, and/or SEQ ID NO: 3, and/or SEQ ID NO: 4, and/or SEQ ID NO: 6. Preferably, the nucleotide sequence encodes a NAD(H)-dependent fumarate reductase comprising the amino acid sequence of SEQ ID NO: 1, and/or SEQ ID NO: 3, and/or SEQ ID NO: 4, and/or SEQ ID NO: 6.
- Sequence identity is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. Usually, sequence identities or similarities are compared over the whole length of the sequences compared. In the art, "identity" also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences.
- Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include BLASTP and BLASTN, publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894). Preferred parameters for amino acid sequences comparison using BLASTP are gap open 11.0, gap extend 1, Blosum 62 matrix.
- Nucleotide sequences encoding the enzymes expressed in the cell of the invention may also be defined by their capability to hybridise with the nucleotide sequences encoding a NAD(H) dependent fumarate reductase of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, and/or SEQ ID NO: 6, under moderate, or preferably under stringent hybridisation conditions. Stringent hybridisation conditions are herein defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and most preferably of about 200 or more nucleotides, to hybridise at a temperature of about 65°C in a solution comprising about 1 M salt, preferably 6 x SSC (sodium chloride, sodium citrate) or any other solution having a comparable ionic strength, and washing at 65°C in a solution comprising about 0.1 M salt, or less, preferably 0.2 x SSC or any other solution having a comparable ionic strength. Preferably, the hybridisation is performed overnight, i.e. at least for 10 hours and preferably washing is performed for at least one hour with at least two changes of the washing solution. These conditions will usually allow the specific hybridisation of sequences having about 90% or more sequence identity.
- Moderate conditions are herein defined as conditions that allow a nucleic acid sequences of at least 50 nucleotides, preferably of about 200 or more nucleotides, to hybridise at a temperature of about 45°C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at room temperature in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength. Preferably, the hybridisation is performed overnight, i.e. at least for 10 hours, and preferably washing is performed for at least one hour with at least two changes of the washing solution. These conditions will usually allow the specific hybridisation of sequences having up to 50% sequence identity. The person skilled in the art will be able to modify these hybridisation conditions in order to specifically identify sequences varying in identity between 50% and 90%.
- To increase the likelihood that an introduced enzyme(s) is / are expressed in active form in a eukaryotic cell of the invention, the corresponding encoding nucleotide sequence may be adapted to optimise its codon usage to that of the chosen eukaryote host cell. Several methods for codon optimisation are known in the art. A preferred method to optimise codon usage of the nucleotide sequences to that of the eukaryotic cell is a codon pair optimization technology as disclosed in
WO2008/000632 . Codon-pair optimization is a method for producing a polypeptide in a host cell, wherein the nucleotide sequences encoding the polypeptide have been modified with respect to their codon-usage, in particular the codon-pairs that are used, to obtain improved expression of the nucleotide sequence encoding the polypeptide and/or improved production of the polypeptide. Codon pairs are defined as a set of two subsequent triplets (codons) in a coding sequence. - The term "gene", as used herein, refers to a nucleic acid sequence containing a template for a nucleic acid polymerase, in eukaryotes, RNA polymerase II. Genes are transcribed into mRNAs that are then translated into protein.
- The term "nucleic acid" as used herein, includes reference to a deoxyribonucleotide or ribonucleotide polymer, i.e. a polynucleotide, in either single-or double-stranded form, and unless otherwise limited, encompasses known analogues having the essential nature of natural nucleotides in that they hybridize to single-stranded nucleic acids in a manner similar to naturally occurring nucleotides (e.g., peptide nucleic acids). A polynucleotide can be full-length or a subsequence of a native or heterologous structural or regulatory gene. Unless otherwise indicated, the term includes reference to the specified sequence as well as the complementary sequence thereof.
- The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The essential nature of such analogues of naturally occurring amino acids is that, when incorporated into a protein, that protein is specifically reactive to antibodies elicited to the same protein but consisting entirely of naturally occurring amino acids. The terms "polypeptide", "peptide" and "protein" are also inclusive of modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation.
- The term "enzyme" as used herein is defined as a protein which catalyses a (bio)chemical reaction in a cell.
- Usually, the nucleotide sequence encoding an enzyme is operably linked to a promoter that causes sufficient expression of the corresponding nucleotide sequence in the eukaryotic cell according to the present invention to confer to the cell the ability to produce succinic acid.
- As used herein, the term "operably linked" refers to a linkage of polynucleotide elements (or coding sequences or nucleic acid sequence) in a functional relationship. A nucleic acid sequence is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
- As used herein, the term "promoter" refers to a nucleic acid fragment that functions to control the transcription of one or more genes, located upstream with respect to the direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences known to one of skilled in the art. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation.
- A promoter that could be used to achieve the expression of a nucleotide sequence coding for an enzyme such as NAD(H)-dependent fumarate reductase or any other enzyme introduced in the eukaryotic cell of the invention, may be not native to a nucleotide sequence coding for the enzyme to be expressed, i.e. a promoter that is heterologous to the nucleotide sequence (coding sequence) to which it is operably linked. Preferably, the promoter is homologous, i.e. endogenous to the host cell.
- Suitable promoters in this context include both constitutive and inducible natural promoters as well as engineered promoters, which are well known to the person skilled in the art. Suitable promoters in eukaryotic host cells may be GAL7, GAL10, or
GAL 1, CYC1, HIS3, ADH1, PGL, PH05, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI, and AOX1. Other suitable promoters include PDC, GPD1, PGK1, TEF1, and TDH. - Usually a nucleotide sequence encoding an enzyme comprises a terminator. Any terminator, which is functional in the eukaryotic cell, may be used in the present invention. Preferred terminators are obtained from natural genes of the host cell. Suitable terminator sequences are well known in the art. Preferably, such terminators are combined with mutations that prevent nonsense mediated mRNA decay in the host cell of the invention (see for example: Shirley et al., 2002, Genetics 161:1465-1482).
- In a preferred embodiment, a nucleotide sequence encoding a NAD(H)-dependent fumarate reductase may be overexpressed to achieve a sufficient production of succinic acid by the cell.
- There are various means available in the art for overexpression of nucleotide sequences encoding enzymes in a eukaryotic cell of the invention. In particular, a nucleotide sequence encoding an enzyme may be overexpressed by increasing the copy number of the gene coding for the enzyme in the cell, e.g. by integrating additional copies of the gene in the cell's genome, by expressing the gene from a centromeric vector, from an episomal multicopy expression vector or by introducing an (episomal) expression vector that comprises multiple copies of the gene. Preferably, overexpression of the enzyme according to the invention is achieved with a (strong) constitutive promoter.
- The invention also relates to a nucleotide construct comprising one or more nucleotide sequence(s) selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 10.
- The nucleic acid construct may be a plasmid, for instance a low copy plasmid or a high copy plasmid. The eukaryotic cell according to the present invention may comprise a single, but preferably comprises multiple copies of the nucleotide sequence encoding a NAD(H) dependent fumarate reductase, for instance by multiple copies of a nucleotide construct.
- The nucleic acid construct may be maintained episomally and thus comprise a sequence for autonomous replication, such as an autosomal replication sequence. If the eukaryotic cell is of fungal origin, a suitable episomal nucleic acid construct may e.g. be based on the yeast 2µ or pKD1 plasmids (Gleer et al., 1991, Biotechnology 9: 968-975), or the AMA plasmids (Fierro et al., 1995, Curr Genet. 29:482-489). Alternatively, each nucleic acid construct may be integrated in one or more copies into the genome of the eukaryotic cell. Integration into the cell's genome may occur at random by non-homologous recombination but preferably, the nucleic acid construct may be integrated into the cell's genome by homologous recombination as is well known in the art.
- The nucleotide sequence encoding a NAD(H)-dependent fumarate reductase, may be a heterologous or a homologous nucleotide sequence. Preferably, the NADH-dependent fumarate reductase is a heterologous enzyme, which may be derived from any suitable origin, for instance bacteria, fungi, protozoa or plants. Preferably, the cell according to the invention comprises hetereologous a NAD(H)-dependent fumarate reductase, preferably derived from a Trypanosoma sp, for instance a Trypanosoma brucei.
- Surprisingly, cytosolic activity of the enzyme resulted in an increased productivity of succinic acid by the eukaryotic cell.
- In the event that the nucleotide sequence encoding a NAD(H)-dependent fumarate reductase comprises a peroxisomal or mitochondrial targeting signal, it may be essential to modify or delete a number of amino acids (and corresponding nucleotide sequences in the encoding nucleotide sequence) in order to prevent peroxisomal or mitochondrial targeting of the enzyme. The presence of a peroxisomal targeting signal may for instance be determined by the method disclosed by Schlüter et al, Nucleic acid Research 2007, 35, D815-D822.
- Preferably, the NAD(H)-dependent fumarate reductase lacks a peroxisomal or mitochondrial targeting signal for cytosolic activity of the enzyme upon expression of the encoding nucleotide sequence.
- Preferably, the cell expresses a nucleotide sequence encoding an enzyme that catalyses the formation of succinic acid, wherein the nucleotide sequence preferably encodes a NAD(H)-dependent fumarate reductase, preferably a fumarate reductase comprising an amino acid sequence that has at least 40%, preferably at least 45, 50, 55, 60, 65 70, 75, 80, 85, 90, 95, 97, 98, 99% sequence identity with the amino acid sequence of SEQ ID NO: 3, and/or SEQ ID NO: 6. Preferably the nucleotide sequence encodes a NAD(H)-dependent fumarate reductase comprising the amino acid sequence of SEQ ID NO: 3, and/or SEQ ID NO: 6.
- The eukaryotic cell selected from the group consisting of a yeast and a filamentous fungus, preferably belongs to one of the genera Saccharomyces, Aspergillus, Penicillium, Pichia, Kiuyveromyces, Yarrowia, Candida, Hansenula, Humicola, Rhizopus, Torulaspora, Trichosporon, Brettanomyces, Zygosaccharomyces, Pachysolen or Yamadazyma. More preferably, the eukaryotic cell is a Saccharomyces cervisiae, Saccharomyces uvarum, Saccharomyces Bayanus, Aspergillus niger, Penicillium chrysogenum, Pichia stipidis, Kluyveromyces marxianus, K. lactis, K. thermotolerans, Yarrowia lipolytica, Candida sonorensis, C. glabrata, Hansenula polymorpha, Torulaspora delbrueckii, Brettanomyces bruxellensis, Rhizopus orizae or Zygosaccharomyces bailii.
- In addition to a nucleotide sequence encoding a NAD(H)-dependent fumarate reductase that catalyses the conversion of fumaric acid to succinic acid, recombinant eukaryotic cell according to the present invention may comprise further genetic modifications, for instance mutations, deletions or disruptions, in homologous nucleotide sequences and/or transformation with nucleotide sequences that encode homologous or heterologous enzymes that catalyse a reaction in the cell resulting in an increased flux towards succinic acid. It may for example be favourable to introduce, genetically modify and/or overexpress heterologous and/or homologous nucleotide sequences encoding i) an enzyme that catalyses the conversion of phosphoenolpyruvate or pyruvate to oxaloacetate; ii) a malate dehydrogenase which catalyses the conversion from OAA to malic acid; or iii) a fumarase, which catalyses the conversion of malic acid to fumaric acid.
- A eukaryotic cell may be transformed or genetically modified with any suitable nucleotide sequence catalyzing the reaction from a C3 to C4 carbon molecule, such as phosphoenolpyruvate (PEP, C3) to oxaloacetate (OAA, C4) and pyruvate (C3) to OAA or malic acid (C3). Suitable enzymes are PEP carboxykinase (EC 4.1.1.49, EC 4.1.1.38) and PEP carboxylase (EC 4.1.1.31) which catalyse the conversion of PEP to OAA; pyruvate carboxylase (EC 6.4.1.1.), that catalyses the reaction from pyruvate to OAA; or malic enzyme (EC 1.1.1.38), that catalyses the reaction from pyruvate to malic acid.
- Preferably a eukaryotic cell according to the present invention overexpresses a nucleotide sequence encoding a pyruvate carboxylase (PYC), preferably a pyruvate carboxylase that is active in the cytosol upon expression of the nucleotide sequence encoding a PYC, for instance a PYC comprising an amino acid sequence according to SEQ ID NO: 41. Preferably, an endogenous or homologous pyruvate carboxylase is overexpressed. Surprisingly, it was found that overexpressing an endogenous pyruvate carboxylase resulted in increased succinic acid production levels by the eukaryotic cell according to the present invention.
- In another preferred embodiment, a eukaryotic cell according to the present invention further comprises a nucleotide sequence encoding a heterologous PEP carboxykinase (EC 4.1.1.49) catalysing the reaction from phosphoenolpyruvate to oxaloacetate. Surprisingly it was found that a eukaryotic cell according to the present invention which further comprises a heterologous PEP carboxykinase produced an increased amount of succinic acid as compared to a eukaryotic cell that does not comprise the heterologous PEP carboxykinase. Preferably, a PEP carboxykinase that is derived from bacteria, more preferably the enzyme having PEP carboxykinase activity is derived from Escherichia coli, Mannheimia sp., Actinobacillus sp., or Anaerobiospirillum sp., more preferably Mannheimia succiniciproducens, Actinobacillus succinogenes, or Anaerobiospirillum succiniciproducens. Preferably, the PEP carboxykinase is active in the cytosol upon expression of the nucleotide sequence encoding PEP carboxykinase since it was found that this resulted in an increase succinic acid production. In one embodiment the PEP carboxykinase of Actinobacillus succinogenes (PCKa) has been modified to replace EGY at position 120-122 with a DAF amino acid sequence. Preferably, a eukaryotic cell according to the present invention comprises a PEP carboxykinase which has at least 80, 85, 90, 95 or 99% sequence identity with SEQ ID NO: 14 or SEQ ID NO: 17, preferably a PEP carboxykinase comprising SEQ ID NO: 14 or SEQ ID NO: 17. Surprisingly it was found that the concomitant (over)expression of a PYC and a PEP carboxykinase as described herein resulted in at least 1.5 increase in succinic acid production.
- In another preferred embodiment a cell according to the present invention further comprises a nucleotide sequence encoding a malate dehydrogenase (MDH) which is active in the cytosol upon expression of the nucleotide sequence. A cytosolic MDH may be any suitable homologous or heterologous malate dehydrogenase. The MDH may be a S. cerevisiae MDH3 or S. cerevisiae MDH1. Preferably, the MDH lacks a peroxisomal or mitochondrial targeting signal in order to localize the enzyme in the cytosol. Alternatively, the MDH is S. cerevisiae MDH2 which has been modified such that it is not inactivated in the presence of glucose and is active in the cytosol. It is known that the transcription of MDH2 is repressed and Mdh2p is degraded upon addition of glucose to glucose-starved cells. Mdh2p deleted for the first 12 amino-terminal amino acids is less-susceptible for glucose-induced degradation (Minard and McAlister-Henn, J. Biol Chem. 1992 Aug 25;267(24):17458-64). Preferably, a eukaryotic cell according to the present invention comprises a nucleotide sequence encoding a malate dehydrogenase that has at least 70%, preferably at least 75, 80, 85, 90, 92, 94, 95, 96, 97, 98, 99% sequence identity with the amino acid sequence of SEQ ID NO: 19 or SEQ ID NO: 21. Preferaby the malate dehydrogenase comprises SEQ ID NO: 19 or SEQ ID NO: 21. Preferably, the activity of malate dehydrogenase is increased by overexpressing the encoding nucleotide sequence by known methods in the art.
- Preferably, a eukaryotic cell according to the present invention further comprises a nucleotide sequence encoding an enzyme that catalyses the conversion of malic acid to fumaric acid, which may be a heterologous or homologous enzyme, for instance a fumarase (FUM). A nucleotide sequence encoding an heterologous enzyme that catalyses the conversion of malic acid to fumaric acid, may be derived from any suitable origin, preferably from microbial origin, preferably from a yeast, for instance Saccharomyces cerevisiae or a filamentous fungus, for instance Rhizopus oryzae. Preferably, a eukaryotic cell according to the present invention comprises a nucleotide sequence encoding a fumarase that has at least 70%, preferably at least 75, 80, 85, 90, 92, 94, 95, 96, 97, 98, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 23. Preferably, the fumarase comprises SEQ ID NO: 23. Preferably the enzyme having fumarase activity is active in the cytosol upon expression of the nucleotide sequence encoding the enzyme having fumarase activity. Surprisingly, it was found that a eukaryotic cell further comprising an enzyme having fumarase activity as described herein produced an increased amount of succinic acid.
- In another embodiment, a eukaryotic cell according to the present invention comprises a nucleotide sequence encoding a dicarboxylic acid transporter protein, preferably a malic acid transporter protein (MAE). A dicarboxylic acid transporter protein may be a homologous or heterologous protein. Preferably the dicarboxylic acid transporter protein is a heterologous protein. A dicarboxylic acid transporter protein may be derived from any suitable organism, preferably from Schizosaccharomyces pombe. Preferably, a dicarboxylic acid transporter protein is a malic acid transporter protein (MAE) which has at least 80, 85, 90, 95 or 99% sequence identity with SEQ ID NO: 36. Preferably the MAE comprises SEQ ID NO: 36. Surprisingly, it was found that a eukaryotic cell according to the present invention further comprising a dicarboxylic acid transporter, such as a malic acid transporter as described herein produced an increased amount of succinic acid as compared to a eukaryote cell not comprising a dicarboxylic acid transporter protein.
- In a preferred embodiment a eukaryotic cell according to the present invention is a yeast comprising nucleotide sequences encoding a NAD(H)-dependent fumarate reductase, a malate dehydrogenase, a heterologous fumarase, a heterologous PEP carboxykinase and a heterologous dicarboxylic acid transporter and overexpresses a pyruvate carboxylase (PYC), as described, including the preferred embodiments, herein above. Surprisingly, it found that a yeast of the invention comprising the nucleotide sequences encoding the enzymes as described herein produced an increased amount of succinic acid as compared to a yeast comprising either of the nucleotide sequences alone.
- In another preferred embodiment a eukaryotic cell according to the present invention comprises reduced activity of enzymes that convert NAD(H) to NAD+ compared to the activity of these enzymes in a wild-type cell.
- Preferably, the cell according to the present invention is a cell wherein at least one gene encoding alcohol dehydrogenase is not functional. An alcohol dehydrogenase gene that is not functional is used herein to describe a eukaryotic cell which comprises a reduced alcohol dehydrogenase activity compared to a cell wherein all genes encoding an alcohol dehydrogenase are functional. A gene may become not functional by known methods in the art, for instance by mutation, disruption, or deletion, for instance by the method disclosed by Gueldener et. al. 2002, Nucleic Acids Research, Vol. 30, No. 6, e23. Preferably, a eukaryotic cell is a yeast cell such as Saccharomyces cerevisiae, wherein one or more genes adh1 and/or adh2, encoding alcohol dehydrogenase are inactivated.
- Preferably, the cell according to the present invention further comprises at least one gene encoding glycerol-3-phosphate dehydrogenase which is not functional. A glycerol-3-phosphate dehydrogenase gene that is not functional is used herein to describe a eukaryotic cell, which comprises a reduced glycerol-3-phosphate dehydrogenase activity, for instance by mutation, disruption, or deletion of the gene encoding glycerol-3-phosphate dehydrogenase, resulting in a decreased formation of glycerol as compared to the wild-type cell. Surprisingly, it was found that the eukaryotic cell comprising reduced alcohol dehydrogenase activity and/or glycerol-3-phosphate dehydrogenase activity and a NAD(H)-dependent fumarase resulted in an increased production of succinic acid as compared to a cell wherein one or more gene(s) encoding alcohol dehydrogenase and/or glycerol-3-phosphate dehydrogenase are not inactivated.
- The present invention also relates to a process for the production of succinic acid comprising fermenting a eukaryotic cell comprising at least one gene encoding alcohol dehydrogenase is not functional and / or at least one gene encoding glycerol-3-phosphate dehydrogenase which is not functional.
- In another preferred embodiment the recombinant eukaryotic cell according to the present invention comprises at least one gene encoding succinate dehydrogenase that is not functional. A succinate dehydrogenase that is not functional is used herein to describe a eukaryotic cell, which comprises a reduced succinate dehydrogenase activity by mutation, disruption, or deletion, of at least one gene encoding succinate dehydrogenase resulting in a increased formation of succinic acid as compared to the wild-type cell. A eukaryotic cell comprising a gene encoding succinate dehydrogenase that is not functional may for instance be Aspergillus niger, preferably an Aspergillus niger, wherein one or more genes encoding succinate dehydrogenase, such as sdhA and sdhB is/are not functional, for instance by deletion of these genes.
- Preferably, a eukaryotic cell according to the invention is a yeast, preferably Saccharomyces cerevisiae, preferably a Saccharomyces cerevisiae comprising one or more of the nucleotide sequences selected from SEQ ID NO: 9 and SEQ ID NO: 10. A eukaryotic cell according to the present invention may also be a filamentous fungus, preferably A. niger, preferably A. niger comprising one or more nucleotide sequences selected from SEQ ID NO: 7 and SEQ ID NO: 8.
- Preferably, a eukaryotic cell according to the present invention comprising any one of the genetic modifications described herein is capable of producing at least 0.3, 0.5, 0.7, g / L succinic acid, preferably at least 1 g / L succinic acid, preferably at least 1.5 preferably at least 2, or 2.5, 4.5 preferably at least 8, 10, 15, or 20 g / L succinic acid but usually below 200 or below 150 g / L.
- A preferred eukaryotic cell according to the present invention may be able to grow on any suitable carbon source known in the art and convert it to succinic acid. The eukaryotic cell may be able to convert directly plant biomass, celluloses, hemicelluloses, pectines, rhamnose, galactose, fucose, maltose, maltodextrines, ribose, ribulose, or starch, starch derivatives, sucrose, lactose and glycerol. Hence, a preferred host organism expresses enzymes such as cellulases (endocellulases and exocellulases) and hemicellulases (e.g. endo- and exo-xylanases, arabinases) necessary for the conversion of cellulose into glucose monomers and hemicellulose into xylose and arabinose monomers, pectinases able to convert pectines into glucuronic acid and galacturonic acid or amylases to convert starch into glucose monomers. Preferably, the cell is able to convert a carbon source selected from the group consisting of glucose, fructose, galactose, xylose, arabinose, sucrose, raffinose, lactose and glycerol.
- In another aspect, the present invention relates to a process for the preparation of succinic acid, comprising fermenting the eukaryotic cell according to the present invention, wherein succinic acid is prepared..
- It was found advantageous to use a eukaryotic cell according to the invention in the process for the production of succinic acid, because most eukaryotic cells do not require sterile conditions for propagation and are insensitive to bacteriophage infections.
- Preferably, the succinic acid that is prepared in the process according to the present invention is further converted into a desirable product. A desirable product may for instance be a polymer, such as polybutylene succinic acid (PBS), a deicing agent, or a surfactant.
- The process according to the present invention may be run under aerobic and anaerobic conditions. Preferably, the process is carried out under anaerobic conditions or under micro-aerophilic or oxygen limited conditions. An anaerobic fermentation process is herein defined as a fermentation process run in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than 5, 2.5 or 1 mmol/L/h, and wherein organic molecules serve as both electron donor and electron acceptors.
- An oxygen-limited fermentation process is a process in which the oxygen consumption is limited by the oxygen transfer from the gas to the liquid. The degree of oxygen limitation is determined by the amount and composition of the ingoing gasflow as well as the actual mixing/mass transfer properties of the fermentation equipment used. Preferably, in a process under oxygen-limited conditions, the rate of oxygen consumption is at least 5.5, more preferably at least 6 and even more preferably at least 7 mmol/L/h.
- The process for the production of succinic acid according to the present invention may be carried out at any suitable pH between 1 and 9. Preferably, the pH in the fermentation broth is between 2 and 7, preferably between 3 and 5. It was found advantageous to be able to carry out the process according to the present invention at a low pH, since this prevents bacterial contamination. In addition, since the pH drops during succinic acid production, a lower amount of titrant may be needed to keep the pH at a desired level.
- A suitable temperature at which the process according to the present invention may be carried out is between 5 and 60°C, preferably between 10 and 50°C, more preferably between 15 and 35°C, more preferably between 18°C and 30°C. The skilled man in the art knows which optimal temperatures are suitable for fermenting a specific eukaryotic cell.
- Preferably, succinic acid is recovered from the fermentation broth by a suitable method known in the art, for instance by crystallisation and ammonium precipitation.
- Preferably, the succinic acid that is prepared in the process according to the present invention is further converted into a pharmaceutical, cosmetic, food, feed, or chemical product. Succinic acid may be further converted into a polymer, such as polybutylene succinate (PBS) or other suitable polymers derived therefrom.
- The present invention also relates to a fermentation broth comprising a succinic acid wherein the fermentation broth is obtainable by a process according to the present invention.
- The invention relates to a process for the production of succinic acid by a yeast or a filamentous fungus as succinic acid producer, whereby fumarate reductase from Trypanosoma brucei is used to increase succinic acid production, wherein preferably the fumarate reductase is active in the cytosol.
- Standard genetic techniques, such as overexpression of enzymes in the host cells, genetic modification of host cells, or hybridisation techniques, are known methods in the art, such as described in Sambrook and Russel (2001) "Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press , or F. Ausubel et al, eds., "Current protocols in molecular biology", Green Publishing and Wiley Interscience, New York (1987). Methods for transformation, genetic modification etc of fungal host cells are known from e.g.
EP-A-0 635 574 ,WO 98/46772 WO 99/60102 WO 00/37671 WO90/14423 EP-A-0481008 ,EP-A-0635 574 andUS 6,265,186 . - The following examples are for illustrative purposes only and are not to be construed as limiting the invention.
-
-
Figure 1 . Map of the pGBTOP-11 vector used for expression of fumarate reductase in A. niger -
Figure 2 : Plasmid map of pGBS414SUS-07, encoding mitochondrial fumarate reductase m1 (FRDm1) from Trypanosoma brucei for expression in Saccharomyces cerevisiae. CPO denotes codon pair optimized. -
Figure 3 : Plasmid map of pGBS414SUS-08, encoding glycosomal fumarate reductase (FRDg) from Trypanosoma brucei for expression in Saccharomyces cerevisiae. CPO denotes codon pair optimized. -
Figure 4 : Plasmid map of pDEL-SDHA -
Figure 5 : Map of plasmid pGBTPAn1, for overexpression FRDm1 in A. niger. -
Figure 6 : Replacement scheme of sdhA -
Figure 7 : Plasmid map of pGBS416FRD-1, encoding mitochondrial fumarate reductase m1 (FRDm1) from Trypanosoma brucei for expression in Saccharomyces cerevisiae. CPO denotes codon pair optimized. -
Figure 8 : Plasmid map of pGBS416FRE-1, encoding glycosomal fumarate reductase (FRDg) from Trypanosoma brucei for expression in Saccharomyces cerevisiae. CPO denotes codon pair optimized. -
Figure 9 : Plasmid map of pGBS414PPK-1, containing PEP carboxykinase from Actinobacillus succinogenes (PCKa) for expression in Saccharomyces cerevisiae. The synthetic gene construct TDH1 promoter-PCKa-TDH1 terminator was cloned into expression vector pRS414. CPO denotes codon pair optimized. -
Figure 10 : Plasmid map of pGBS414PPK-2, containing PEP carboxykinase from Actinobacillus succinogenes (PCKa) and mitochondrial fumarate reductase m1 from Trypanosoma brucei (FRDm1) for expression in Saccharomyces cerevisiae. The synthetic gene constructs TDH1 promoter-PCKa-TDH1 terminator and TDH3 promoter-FRDm1-TDH3 terminator were cloned into expression vector pRS414. CPO denotes codon pair optimized. -
Figure 11 : Plasmid map of pGBS414PPK-3, containing PEP carboxykinase from Actinobacillus succinogenes (PCKa) and glycosomal fumarate reductase from Trypanosoma brucei (FRDg) for expression in Saccharomyces cerevisiae. The synthetic gene constructs TDH1 promoter-PCKa-TDH1 terminator and TDH3 promoter-FRDg-TDH3 terminator were cloned into expression vector pRS414. CPO denotes codon pair optimized. -
Figure 12 : Plasmid map of pGBS414PEK-1, containing PEP carboxykinase from Mannheimia succiniciproducens (PCKm) for expression in Saccharomyces cerevisiae. The synthetic gene construct TDH1 promoter-PCKm-TDH1 terminator was cloned into expression vector pRS414. CPO denotes codon pair optimized. -
Figure 13 : Plasmid map of pGBS414PEK-2, containing PEP carboxykinase from Mannheimia succiniciproducens (PCKm) and mitochondrial fumarate reductase m1 from Trypanosoma brucei (FRDm1) for expression in Saccharomyces cerevisiae. The synthetic gene constructs TDH1 promoter-PCKm-TDH1 terminator and TDH3 promoter-FRDm1-TDH3 terminator were cloned into expression vector pRS414. CPO denotes codon pair optimized. -
Figure 14 : Plasmid map of pGBS414PEK-3, containing PEP carboxykinase from Mannheimia succiniciproducens (PCKm) and glycosomal fumarate reductase from Trypanosoma brucei (FRDg) for expression in Saccharomyces cerevisiae. The synthetic gene constructs TDH1 promoter-PCKm-TDH1 terminator and TDH3 promoter-FRDg-TDH3 terminator were cloned into expression vector pRS414. CPO denotes codon pair optimized. -
Figure 15 : Plasmid map of pGBS415FUM-2, containing fumarase from Rhizopus oryzae (FUMR) and cytoplasmic malate dehydrogenase from Saccharomyces cerevisiae truncated for the first 12 amino acids (deltal2N MDH2) for expression in Saccharomyces cerevisiae. The synthetic gene constructs TDH1 promoter-FUMR-TDH1 terminator and DH3 promoter MDH3-TDH3 terminator were cloned into expression vector pRS415. CPO denotes codon pair optimized. -
Figure 16 : Plasmid map of pGBS415FUM-3, containing fumarase from Rhizopus oryzae (FUMR) and peroxisomal malate dehydrogenase from Saccharomyces cerevisiae (MDH3) for expression in Saccharomyces cerevisiae. The synthetic gene constructs TDH1 promoter-FUMR-TDH1 terminator and TDH3 promoter-MDH3-TDH3 terminator were cloned into expression vector pRS415. CPO denotes codon pair optimized. -
Figure 17 : Succinic acid levels in strains SUC-101 (○, empty vectors control), SUC-148 (■, overexpression of PCKa, MDH3, FUMR, FRDm1), SUC-149 (□, PCKa, MDH3, FUMR, FRDg), SUC-150 (◆, PCKm, MDH3, FUMR, FRDm1), SUC-151 (◊, PCKm, MDH3, FUMR, FRDg), SUC-152 (●, PCKa, MDH3, FUMR), SUC-154 (X, PCKm, MDH3, FUMR) and SUC-169 (▲, PCKm, delta12NMDH2, FUMR, FRDm1). All overexpressed genes were codon pair optimized for expression in S. cerevisiae. All data represent averages of 3 independent growth experiments of SUC-148, 149, 150, 151, 152, 154 and SUC-169 and averages of 6 independent growth experiments of SUC-101. -
Figure 18 : Plasmid map of pGBS416MAE-1, containing malate permease from Schizosaccharomyces pombe (SpMAE1) for expression in Saccharomyces cerevisiae. The synthetic gene construct Eno1 promoter-MAE1-Eno1 terminator was cloned into expression vector pRS41.6. CPO denotes codon pair optimized. -
Figure 19 : Succinic acid levels in strains SUC-101 (○, empty vectors control), SUC-169 (▲, PCKm, delta12NMDH2, FUMR, FRDm1) and SUC-194 (■,PCKm, delta12NMDH2, FUMR, FRDm1, SpMAE1). All overexpressed genes were codon pair optimized for expression in S. cerevisiae. All data represent averages of 3 independent growth experiments of SUC-169 and SUC-194 and averages of 6 independent growth experiments of SUC-101. -
Figure 20 : Succinic acid levels in strains SUC-103 (○, adh1/2 and gpd1 deletion mutant; empty vectors control), SUC-201 (□,adh1/2 and gpd1 deletion mutant; PCKa; MDH3, FUMR, FRDg) and SUC-200 (■,adh1/2 and gpd1 deletion mutant; PCKa, MDH3, FUMR, FRDg, SpMAE1). All overexpressed genes were codon pair optimized for expression in S. cerevisiae. -
Figure 21 : Plasmid map of pGBS426PYC-2, containing pyruvate carboxylase from Saccharomyces cerevisiae for expression in Saccharomyces cerevisiae. The PYC2 coding nucleotide sequence was obtained by PCR using genomic DNA from strain CEN.PK113-5D as template and the PCR product was cloned into expression vector p426GPD. -
Figure 22 : Plasmid map of pGBS414FRE-1, encoding glycosomal fumarate reductase (FRDg) from Trypanosoma brucei for expression in Saccharomyces cerevisiae. The synthetic gene construct TDH3 promoter-FRDg-TDH3 terminator was cloned into expression vector pRS414. -
Figure 23 : Succinic acid levels in strains SUC-226 (□, PCKa, MDH3, FUMR, FRDg),-227 (▲, PYC2, PCKa, MDH3, FUMR, FRDg), SUC-228 (■, PYC2, MDH3, FUMR, FRDg) and SUC-230 (○, MDH3, FUMR, FRDg). Data represents the average of 3 independent growth experiments. - Mitochondrial fumarate reductase m1 (FRDm1) [E.C. 1.3.1.6], GenBank accession number 60460035, from Trypanosoma brucei was analysed for the presence of signal sequences using SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/) Bendtsen, J. et al. (2004) Mol. Biol., 340:783-795 and TargetP 1.1 (http://www.cbs.dtu.dk/services/TargetP/) Emanuelsson, O. et al. (2007) . A putative mitochondrial targeting sequence in the N-terminal half of the protein was identified, including a possible cleavage site between pos. 25 and 26 (D-S).
- It was shown that FRDm1 recombinant protein lacking the 68 N-terminal residues, relocalized to the cytosol of the procyclic trypanosomes (Coustou et al., J Biol Chem. 2005 Apr 29;280(17):16559-70). These results indicate that the predicted N-terminal signal motif of FRDm1 is required for targeting to the mitochondrion. The first 68 amino acids were removed from SEQ ID NO: 1 (corresponding to nucleotide sequence SEQ ID NO: 2) and a new methionine amino acid was reintroduced, which resulted in SEQ ID NO: 3. SEQ ID NO: 3 was subjected to the codon-pair method as disclosed in
WO2008/000632 for A. niger. The resulting sequence SEQ ID NO: 7 was put behind the constitutive GPDA promoter sequence SEQ ID NO: 11, wherein the last 10 nucleotide sequences were replaced with optimal Kozak sequence CACCGTAAA. Convenient restriction sites were added. The stop codon TAA in SEQ: ID NO: 7 was modified to TAAA. The resulting sequence was synthesised at Sloning (Puchheim, Germany). The fragment was SnaBI, SfiI cloned in the A. niger expression vector pGBTOP11 (Figure 1 ) using appropriate restriction sites. The resulting plasmid comprising FRDm1 was named pGBTOPAn1 (Figure 5 ). - Likewise, glycosomal fumarate reductase (FRDg) [E.C. 1.3.1.6], GenBank accession number 23928422, from Trypanosoma brucei was analysed for peroxisomal targeting in filamentous fungi using the PTS1 predictor httg:/imendel.imp.ac.at/mendeljsp/sat/pts1/PRS1predictor.jsp with the fungi-specific prediction function. The C-terminal amino acids at position 1140-1142 (SKI) were removed from the protein SEQ ID NO: 4 (corresponding to nucleotide sequence SEQ ID NO: 5), resulting in SEQ ID NO: 6. SEQ ID NO: 6, was subjected to the codon-pair method as disclosed in
PCT/EP2007/05594 Figure 1 ) using appropriate restriction sites. - A. niger WT-1: This A. niger strain is CBS513.88 comprising deletions of the genes encoding glucoamylase (glaA), fungal amylase and acid amylase.
A. niger WT 1 was constructed by using the "MARKER-GENE FREE" approach as described inEP 0 635 574 B1 - The expression constructs are co-transformed to strain A. niger WT-1 according to the method described by Tilburn, J. et al. (1983) Gene 26, 205-221 and Kelly, J. & Hynes, M. (1985) EMBO J., 4, 475-479 with the following modifications:
- Spores are germinated and cultivated for 16 hours at 30 degrees Celsius in a shake flask placed in a rotary shaker at 300 rpm in Aspergillus minimal medium (100ml). Aspergillus minimal medium contains per litre: 6 g NaNO3, 0.52 g KCI, 1.52 g KH2PO4, 1.12 ml 4 M KOH, 0.52 g MgSO4.7H2O, 10 g glucose, 1 g casaminoacids, 22 mg ZnSO4.7H2O, 11 mg H3BO3, 5 mg FeSO4.7H2O, 1.7 mg CoCl2.6H2O, 1.6 mg CuSO4.5H2O, 5 mg MnCl2.2H2O, 1.5 mg Na2MoO4.2H2O, 50 mg EDTA, 2 mg riboflavin, 2 mg thiamine-HCl, 2 mg nicotinamide, 1 mg pyridoxine-HCL, 0.2 mg panthotenic acid, 4 g biotin, 10 ml Penicillin (5000 IU/ml) Streptomycin (5000 UG/ml) solution (Gibco).
- Novozym 234™ (Novo Industries) instead of helicase is used for the preparation of protoplasts;
- After protoplast formation (60-90 minutes), KC buffer (0.8 M KCI, 9.5 mM citric acid, pH 6.2) is added to a final volume of 45 ml, the protoplast suspension is centrifuged for 10 minutes at 3000 rpm at 4 degrees Celsius in a swinging-bucket rotor. The protoplasts are resuspended in 20 ml KC buffer and subsequently 25 ml of STC buffer (1.2 M sorbitol, 10 mM Tris-HCl pH 7.5, 50 mM CaCl2) iss added. The protoplast suspension is centrifuged for 10 minutes at 3000 rpm at 4 degrees Celsius in a swinging-bucket rotor, washed in STC-buffer and resuspended in STC-buffer at a concentration of 10E8 protoplasts/ml;
- To 200 microliter of the protoplast suspension, the DNA fragment, dissolved in 10 microliter TE buffer (10 mM Tris-HCl pH 7.5, 0.1 mM EDTA) and 100 microliter of PEG solution (20% PEG 4000 (Merck), 0.8 M sorbitol, 10 mM Tris-HCl pH 7.5, 50 mM CaCl2) is added;
- After incubation of the DNA-protoplast suspension for 10 minutes at room temperature, 1.5 ml PEG solution (60% PEG 4000 (Merck), 10 mM Tris-HCl pH 7.5, 50 mM CaCl2) is added slowly, with repeated mixing of the tubes. After incubation for 20 minutes at room temperature, suspensions are diluted with 5 ml 1.2 M sorbitol, mixed by inversion and centrifuged for 10 minutes at 4000 rpm at room temperature. The protoplasts are resuspended gently in 1 ml 1.2 M sorbitol and plated onto solid selective regeneration medium consisting of either Aspergillus minimal medium without riboflavin, thiamine.HCL, nicotinamide, pyridoxine, panthotenic acid, biotin, casaminoacids and glucose. In case of acetamide selection the medium contains 10 mM acetamide as the sole nitrogen source and 1 M sucrose as osmoticum and C-source. Alternatively, protoplasts are plated onto PDA (Potato Dextrose Agar, Oxoid) supplemented with 1-50 microgram/ml phleomycin and 1M sucrose as osmosticum. Regeneration plates are solidified using 2% agar (agar No.1, Oxoid L11). After incubation for 6-10 days at 30 degrees Celsius, conidiospores of transformants are transferred to plates consisting of Aspergillus selective medium (minimal medium containing acetamide as sole nitogen source in the case of acetamide selection or PDA supplemented with 1-50 microgram/ml phleomycin in the case of phleomycin selection) with 2% glucose and 1.5% agarose (Invitrogen) and incubated for 5-10 days at 30 degrees Celsius. Single transformants are isolated and this selective purification step is repeated once upon which purified transformants are stored.
- In total 10 transformants are selected for each construct and the presence of the construct is confirmed by PCR using primers specific for the constructs. Subsequently spores are inoculated in 100ml Aspergillus minimal enriched medium comprising 100g/l glucose. Strains are grown in an incubator at 250 rotations per minute for four days at 34 degrees Celsius. The supernatant of the culture medium is analysed for oxalic acid, malic acid, fumaric acid and succinic acid formation by HPLC and compared to a non transformed strain.
- HPLC is performed for the determination of organic acids and sugars in different kinds of samples. The principle of the separation on a Phenomenex Rezex-RHM-Monosaccharide column is based on size exclusion, ion-exclusion and ion-exchange using reversed phase mechanisms. Detection takes place by differential refractive index and ultra violet detectors.
- Mitochondrial fumarate reductase m1 (FROm1) [E.C. 1.3.1.6], GenBank accession number 60460035, from Trypanosoma brucei was analysed for the presence of signal sequences and codon optimized as described in section 1.1 for expression in S. cerevisiae. The resulting sequence SEQ ID NO: 9 was put behind the constitutive TDH3 promoter sequence SEQ ID NO: 12 and before the TDH3 terminator sequence SEQ ID NO: 13, and convenient restriction sites were added. The stop codon TGA in SEQ ID NO: 9 was modified to TAAG. The resulting sequence was synthesised at Sloning (Puchheim, Germany). The expression construct pGBS414SUS-07 was created after a BamHI/NotI restriction of the S. cerevisiae expression vector pRS414 (Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27) and subsequently ligating in this vector a BamHI/NotI restriction fragment consisting of the fumarate reductase synthetic gene construct (
Figure 2 ). The ligation mix is used for transformation of E. coli DH10B (Invitrogen) resulting in the yeast expression construct pGBS414SUS-07 (Figure 2 ). - Likewise, glycosomal fumarate reductase (FRDg) [E.C. 1.3.1.6], GenBank accession number 23928422, from Trypanosoma brucei was analysed for peroxisomal targeting and codon optimisation was applied as described in section 1.1 for expression in S. cerevisiae. The resulting sequence SEQ ID NO: 10 was put behind the constitutive TDH3 promoter sequence SEQ ID NO: 12 and before the TDH3 terminator sequence SEQ ID NO: 13, and convenient restriction sites were added. The stop codon TGA in SEQ ID NO: 10 was modified to TAAG. The resulting sequence was synthesised at Sloning (Puchheim, Germany). The expression construct pGBS414SUS-08 was created after a BamHI/NotI restriction of the S. cerevisiae expression vector pRS414 (Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27) and subsequently ligating in this vector a BamHI/NotI restriction fragment consisting of the fumarate reductase synthetic gene construct (
Figure 3 ). The ligation mix is used for transformation of E. coli DH10B (Invitrogen) resulting in the yeast expression construct pGBS414SUS-08 (Figure 3 ). - The constructs pGBS414SUS-07 and pGBS414SUS-08 are independently transformed into S. cerevisiae strains CEN.PK113-6B (MATA ura3-52 leu2-112 trp1-289), RWB066 (MATA ura3-52 leu2-112 trp1-289 adh1::lox adh2::Kanlox) and RWB064 (MATA ura3-52 leu2-112 trp1-289 adh1::lox adh2::lox gpd1::Kanlox). Transformation mixtures are plated on Yeast Nitrogen Base (YNB) w/o AA (Difco) + 2% glucose supplemented with appropriate amino acids. Transformants are inoculated in Verduyn medium comprising glucose supplemented with appropriate amino acids (Verduyn et al., 1992, Yeast. Jul;8(7):501-17) and grown under aerobic, anaerobic and oxygen-limited conditions in shake flasks. The medium for anaerobic cultivation is supplemented with 0.01 g/l ergosterol and 0.42 g/l Tween 80 dissolved in ethanol (Andreasen and Stier, 1953, J. cell. Physiol, 41, 23-36; Andreasen and Stier, 1954, J. Cell. Physiol, 43: 271-281). All yeast cultures are grown at 30°C in a shaking incubator at 250-280 rpm. At different incubation times, aliquots of the cultures are removed, centrifuged and the medium is analysed by HPLC for formation of oxalic acid, malic acid, fumaric acid and succinic acid as described in section 1.4.
- In a similar way as disclosed in Example 2A.1. mitochondrial fumarate reductase from Trypanosoma brucei (FRDm, SEQ ID NO: 9) was ligated in a S. cerevisiae expression vector pRS416 (Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27). The ligation mix was used for transformation of E. coli TOP10 cells (Invitrogen) resulting in the yeast expression constructs and pGBS416FRD-1 (
Figure 7 ). - Likewise, glycosomal fumarate reductase (FRDg, SEQ ID NO: 10) from Trypanosoma brucei was ligated in an S. cerevisiae expression vector pRS416. The ligation mix was used for transformation of E. coli TOP10 cells (Invitrogen) resulting in the yeast expression construct pGBS416FRE-1 (
Figure 8 ). - The constructs pGBS416FRD-1 and pGBS416FRE-1 were independently transformed into S. cerevisiae strain CEN.PK113-5D (MATA ura3-52). As negative control, empty vector pRS416 was transformed into strain CEN.PK 113-5D. Transformation mixtures were plated on Yeast Nitrogen Base (YNB) w/o AA (Difco) + 2% glucose. The following numbers of individual transformants were inoculated in duplo in 250 microlitres Verduyn medium comprising 2% glucose in 96 deep-well MTP's and pre-cultured at 30 degrees Celsius, 550 rpm, and a humidity of 80% in an Infors Microplate shaking incubator: 12 pGBS416FRD-1 (FRDm1), 12 pGBS416FRE-1 (FRDg) and 24 pRS416 empty vector control transformants. After 3 days, 25 microlitres of the pre-culture present in the wells of the MTP plates was transferred to new 96 deep-well MTP's containing Verduyn medium containing glucose and CaCO3 (end-concentrations:
glucose 10%,CaCO3 1% w/v in a total volume of 250 microlitres). After 3 and 7 days of growth at 30°C, 550 rpm, and a humidity of 80% in an Infors Microplate shaking incubator, the MTP's were centrifuged for 2 minutes at 2000 rpm, and 200 microliters of supernatant was harvested using the Multimek 96 (Beckman). The supernatant was analyzed by HPLC as described in Example 1.4 for the presence succinic acid. The results are shown in Table 1.Table 1. Effect of introduction of mitochondrial (FRDm1) and glycosomal fumarate reductase (FRDg) from T. brucei in S. cerevisiae on the succinic acid production levels after 3 and 7 days of incubation S. cerevisiae comprising plasmid: Succinic acid (mg/l) after 3 days Succinic acid (mg/l) after 7 days Empty vector pRS416 138±18 (n=48) 203±48 (n=48) pGBS416FRD-1 (FRDm1) 340±65 (n=24) 399±72 (n=24) pGBS416FRE-1 (FRDg) 489±30 (n=24) 516±57 (n=24) - The results in Table 1 show that introduction and overexpression of mitochondrial fumarate reductase (FRDm1) from T. brucei resulted in increased succinic acid production levels (2.47 fold, p=6.96E-14, Student's t-test, after 3 days incubation and 1.97 fold, p=8.63E-14, Student's t-test after 7 days incubation).
- Likewise, introduction and overexpression of glycosomal fumarate reductase (FRDg) from T. brucei resulted in increased succinic acid production levels (3.55 fold, p=5.08E-32, Student's t-test, after 3 days incubation and a 2.55 fold increase, p=8.63E-25, Student's t-test after 7 days incubation).
- Phosphoenolpyruvate carboxykinase [E.C. 4.1.1.49], GenBank accession number 152977907, from Actinobacillus succinogenes was analysed for the presence of signal sequences using SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/) Bendtsen, J. et al. (2004) Mol. Biol., 340:783-795 and TargetP 1.1 (http://www.cbs.dtu.dk/services/TargetP/) Emanuelsson, O. et al. (2007) . Analysis as described by Schlüter et al., (2007) NAR, 35, D815-D822 revealed a putative PTS2 signal sequence at position 115-123. The A. succinogenes sequence was modified to resemble the Mannheimia succiniciproducens protein sequence by replacing the amino acids EGY at position 120-122 with DAF resulting in amino acid sequence SEQ ID NO: 14 (nucleotide sequence SEQ ID NO: 15). SEQ ID NO: 14 was subjected to the codon-pair method as disclosed in
WO2008/000632 for S. cerevisiae. The stop codon TAA in the resulting nucleotide sequence SEQ ID NO: 16 was modified to TAAG. This SEQ ID NO: 16 containing stop codon TAAG was put behind the constitutive TDH1 promoter sequence SEQ ID NO: 25 and before the TDH1 terminator sequence SEQ ID NO: 26, and convenient restriction sites were added. The resulting sequence SEQ ID NO: 29 was synthesised at Sloning (Puchheim, Germany). - Likewise phosphoenolpyruvate carboxykinase [E.C. 4.1.1.49], GenBank accession number 52426348, from Mannheimia succiniciproducens was analysed for the presence of signal sequences as described in Schlüter et al., (2007) NAR, 35, D815-D822. The sequence as shown in SEQ ID NO: 17 required no modifications. SEQ ID NO: 17 was subjected to the codon-pair method as disclosed in
WO2008/000632 for S. cerevisiae. The stop codon TAA in the resulting sequence SEQ ID NO: 18 was modified to TAAG. SEQ ID NO: 18 containing stop codon TAAG was put behind the constitutive TDH1 promoter sequence SEQ ID NO: 25 and before the TDH1 terminator sequence SEQ ID NO: 26. Convenient restriction sites were added. The resulting synthetic construct (SEQ ID NO: 30) was synthesised at Sloning (Puchheim, Germany). - Cytoplasmic malate dehydrogenase (Mdh2p) [E.C. 1.1.1.37], GenBank accession number 171915, is regulated by carbon catabolite repression: transcription of MDH2 is repressed and Mdh2p is degraded upon addition of glucose to glucose-starved cells. Mdh2p deleted for the 12 amino-terminal amino acids is less-susceptible for glucose-induced degradation (Minard and McAlister-Henn, J Biol Chem. 1992 Aug 25;267(24):17458-64). To avoid glucose-induced degradation of Mdh2, the nucleotides encoding the first 12 amino acids were removed, and a new methionine amino acid was introduced (SEQ ID NO: 19) for overexpression of Mdh2 in S. cerevisiae. SEQ ID NO: 19 was subjected to the codon-pair method as disclosed in
WO2008/000632 for S. cerevisiae. The stop codon TAA in the resulting in SEQ ID NO: 20, was modified to TAAG. SEQ ID NO: 20 containing a modified stop codon TAAG, encoding delta12NMDH2, was put behind the constitutive TDH3 promoter sequence SEQ ID NO: 12 and before the TDH3 terminator sequence SEQ ID NO: 13, and convenient restriction sites were added. The resulting synthetic construct (SEQ ID NO: 31) was synthesised at Sloning (Puchheim, Germany). - Peroxisomal malate dehydrogenase (Mdh3p) [E.C. 1.1.1.37], GenBank accession number 1431095, was analysed for peroxisomal targeting in filamentous fungi using the PTS1 predictor http://mendel.imp.ac.at/mendeljsp/sat/pts1/PTS1predictor.jsp with the fungi-specific prediction function. The C-terminal amino acids at position 341-343 (SKL) were removed from protein MDH3 resulting in SEQ ID NO: 21. SEQ ID NO: 21 was subjected to the codon-pair method as disclosed in
WO2008/000632 for S. cerevisiae. The stop codon TGA in the resulting sequence SEQ ID NO: 22 was modified to TAAG. SEQ ID NO: 22 containing TAAG as stop codon was synthesized behind the constitutive TDH3 promoter sequence SEQ ID NO: 27 (600 bp upstream of start codon) and before the TDH3 terminator sequence SEQ ID NO: 28 (300 bp downstram of stop codon), and convenient restriction sites were added. The resulting sequence SEQ ID NO: 32 was synthesised at Sloning (Puchheim, Germany). - Fumarase [E.C. 4.2.1.2], GenBank accession number 469103, from Rhizopus oryzae (FumR) was analysed for the presence of signal sequences using SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/) Bendtsen, J. et al. (2004) Mol. Biol., 340:783-795 and TargetP 1.1 (http://www.cbs.dtu.dk/services/TargetP/) Emanuelsson, O. et al. (2007) . A putative mitochondrial targeting sequence in the first 23 amino acid of the protein was identified. To avoid potential targeting to mitochondria in S. cerevisiae, the first 23 amino acids were removed from FumR and a methionine amino acid was reintroduced resulting in SEQ ID NO: 23. SEQ ID NO: 23 was subjected to the codon-pair method as disclosed in
WO2008/00063 - Gene sequences of mitochondrial fumarate reductase (FRDm1) and glycosomal fumarate reductase (FRDg) from T. brucei were designed and synthesized as described under 2A.1.
- The expression constructs pGBS414PPK-1 (
Figure 9 ), pGBS414PPK-2 (Figure 10 ) and pGBS414PPK-3 (Figure 11 ) were created after a BamHI/NotI restriction of the S. cerevisiae expression vector pRS414 (Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27) and subsequently ligating in this vector a BamHI/NotI restriction fragment consisting of the phosphoenolpyruvate carboxykinase (origin Actinobacillus succinogenes) synthetic gene construct (SEQ ID NO: 29). The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS414PPK-1. Subsequently, pGBK414PPK-1 was restricted with AscI and NotI. To create pGBS414PPK-2, an AscI/NotI restriction fragment consisting of mitochondrial fumarate reductase from T. brucei (FRDm1) synthetic gene construct (SEQ ID NO: 34) was ligated into the restricted pGBS414PPK-1 vector. The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS414PPK-2 (Figure 10 ). To create pGBS414PPK-3, an AscI/NotI restriction fragment consisting of glycosomal fumarate reductase from T. brucei (FRDg) synthetic gene construct (SEQ ID NO: 35) was ligated into the restricted pGBS414PPK-1 vector. The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS414PPK-3 (Figure 11 ). - The expression constructs pGBS414PEK-1 (
Figure 12 ), pGBS414PEK-2 (Figure 13 ) and pGBS414PEK-3 (Figure 14 ) were created after a BamHI/NotI restriction of the S. cerevisiae expression vector pRS414 (Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27) and subsequently ligating in this vector a BamHI/NotI restriction fragment consisting of the phosphoenolpyruvate carboxykinase (origin Mannheimia succiniciproducens) synthetic gene construct (SEQ ID NO: 30). The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS414PEK-1. Subsequently, pGBK414PEK-1 was restricted with AscI and NotI. To create pGBS414PEK-2, an AscI/NotI restriction fragment consisting of mitochondrial fumarate reductase from T. brucei (FRDm1) synthetic gene construct (SEQ ID NO: 34) was ligated into the restricted pGBS414PEK-1 vector. The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS414PEK-2 (Figure 13 ). To create pGBS414PEK-3, an AscI/NotI restriction fragment consisting of glycosomal fumarate reductase from T. brucei (FRDg) synthetic gene construct (SEQ ID NO: 35) was ligated into the restricted pGBS414PEK-1 vector. The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS414PEK-3 (Figure 14 ). - The expression constructs pGBS415FUM-2 (
Figure 15 ) and pGBS415FUM-3 (Figure 16 ) were created after a BamHI/NotI restriction of the S. cerevisiae expression vector pRS415 (Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27) and subsequently ligating in this vector a BamHI/NotI restriction fragment consisting of the fumarase (origin Rhizopus oryzae) synthetic gene construct (SEQ ID NO: 33). The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS415FUM-1. Subsequently, pGBK415FUM-1 was restricted with AscI and NotI. To create pGBS415FUM-2, an AscI/NotI restriction fragment consisting of cytoplasmic malate dehydrogenase from S. cerevisiae (delta12N MDH2) synthetic gene construct (SEQ ID NO: 31) was ligated into the restricted pGBS415FUM-1 vector. The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS415FUM-2 (Figure 15 ). To create pGBS415FUM-3, an AscI/NotI restriction fragment consisting of peroxisomal malate dehydrogenase from S. cerevisiae (MDH3) synthetic gene construct (SEQ ID NO: 32) was ligated into the restricted pGBS415FUM-1 vector. The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS415FUM-3 (Figure 16 ). - Different combinations of plasmids pGBS414PPK-1, pGBS414 PPK-2, pGBS414PPK-3, pGBS414PEK-1, pGBS414PEK-2, pGBS414PEK-3, pGBS415FUM-2, pGBS415-FUM-3 were transformed into S. cerevisiae strain CEN.PK113-6B (MATA ura3-52 leu2-112 trp1-289), resulting in the yeast strains depicted in Table 2. In addition to the mentioned plasmids, pRS416 (empty vector) was transformed to create prototrophic yeast strains. The expression vectors were transformed into yeast by electroporation. The transformation mixtures were plated on Yeast Nitrogen Base (YNB) w/o AA (Difco) + 2% glucose.
Table 2: Yeast strains constructed for Example 2C. Name Background Plasmids Genes SUC-148 CEN.PK113-6B pGBS414PPK-2 PCKa, FRDm1 pGBS415FUM-3 FUMR, MDH3 pRS416 (empty vector) SUC-149 CEN.PK113-6B pGBS414PPK-3 PCKa, FRDg pGBS415FUM-3 FUMR, MDH3 pRS416 (empty vector) SUC-150 CEN.PK113-6B pGBS414PEK-2 PCKm, FRDm1 pGBS415FUM-3 FUMR, MDH3 pRS416 (empty vector) SUC-151 CEN.PK113-6B pGBS414PEK-3 PCKm,FRDg pGBS415FUM-3 FUMR, MDH3 pRS416 (empty vector) SUC-152 CEN.PK113-6B pGBS414PPK-1 PCKa pGBS415FUM-3 FUMR, MDH3 pRS416 (empty vector) SUC-154 CEN.PK113-6B pGBS414PEK-1 PCKm pGBS415FUM-3 FUMR, MDH3 pRS416 (empty vector) SUC-169 CEN.PK113-6B pGBS414PEK-2 PCKm, FRDm1 pGBS415FUM-2 FUMR, Δ12NMDH2 pRS416 (empty vector) SUC-101 CEN.PK113-6B pRS414 (empty vector) pRS415 (empty vector) pRS415 (empty vector) - Transformants were inoculated in 20 ml pre-culture medium consisting of Verduyn medium (Verduyn et al., 1992, Yeast. Jul;B(7):501-17) comprising 2% galactose (w/v) and grown under aerobic conditions in 100 ml shake flasks in a shaking incubator at 30°C at 250 rpm. After 72 hours, the culture was centrifuged for 5 minutes at 4750 rpm. 1 ml supernatant was used to measure succinic acid levels by HPLC as described in section 1.4. The remaining supernatant was decanted and the pellet (cells) was resuspended in 1 ml production medium. The production medium consisted of Verduyn medium with 10 % galactose (w/v) and 1% CaCO3 (w/v). The resuspended cells were inoculated in 50 ml production medium in 100 ml shake flasks and grown in a shaking incubator at 30°C at 100 rpm. At various time points, 1 ml sample was taken from the culture succinic acid levels were measured by HPLC as described in section 1.4 (
Figure 17 ). - Strains transformed with empty vectors (control strain) produced up to 0.3 g/L succinic acid. Overexpression of PEP carboxykinase from M. succiniciproducens (PCKm), peroxisomal malate dehydrogenase (MDH3) from S. cerevisiae and fumarase from R. oryzae (FUMR) resulted in production of 0.9 g/L succinic acid production. Overexpression of PEP carboxykinase from A. succinogenes (PCKa), MDH3 and FUMR resulted in a slight increase in succinic acid production to 1.0 g/L.
- These results show that in S. cerevisiae as decribed increased succinic acid production about 3 times.
- Additional overexpression of mitochondrial fumarate reductase (FRDm1) from T. brucei further increased succinic acid production levels; overexpression of PCKa, MDH3, FUMR, FRDm1 resulted in production of 2.6 g/L succinic acid, and overexpression of PCKm, MDH3, FUMR and FRDm1 resulted in production of 2.7 g/L succinic acid. Overexpression of delta12NMDH2 in combination with PCKm, FUMR and FRDm1 resulted in production of 2.7 g/L succinic acid, indicating that similar levels of succinic acid were produced using either truncated MDH2 or MDH3. Additional overexpression of glycosomal fumarate reductase (FRDg) from T. brucei resulted in an even higher increase in succinic acid production levels; overexpression of PCKa, MDH3, FUMR and FRDg resulted in production of 3.9 g/L succinic acid, whereas overexexpression of PCKm, MDH3, FUMR and FRDg resulted in slightly lower production of 3.6 g/L succinic acid.
- The results show addition of NAD(H) dependent fumarate reductase as disclosed herein in a S. cerevisiae comprising a genetic modification of PCKa/m, MDH3 and FUMR significantly increased succinic acid production levels.
- Overexpression of FRDg had a more positive effect on succinic acid production levels in S. cerevisiae compared to overexpression of FRDm1 in S. cerevisiae.
- Malate permease, GenBank accession number 119368831, from Schizosaccharomyces pombe (SEQ ID NO: 36) was subjected to the codon-pair method as disclosed in
WO2008/000632 for S. cerevisiae resulting in SEQ ID NO: 37. The stop codon TAA in SEQ ID NO: 37 was modified to TAAG. SEQ ID NO: 37 containing TAAG as stop codon was put behind the constitutive ENO1 promoter sequence SEQ ID NO: 38 and before the ENO1 terminator sequence SEQ ID NO: 39, and convenient restriction sites were added. In the ENO1 promotor, T at position 596 (-5) was changed to A in order to obtain a better Kozak sequence. The resulting sequence SEQ ID NO: 40 was synthesised at Sloning (Puchheim, Germany): - The expression constructs pGBS416MAE-1 (
Figure 18 ) was created after a BamHI/NotI restriction of the S. cerevisiae expression vector pRS416 (Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27) and subsequently ligating in this vector a BamHI/NotI restriction fragment consisting of the Schizosaccharomyces pombe malate transporter synthetic gene construct (SEQ ID NO: 40). The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS416MAE-1. - Plasmids pGBS414PEK-2, pGBS415FUM-2 and pGBS416MAE-1 (described under 2C.2.) were transformed into S. cerevisiae strain CEN.PK113-6B (MATA ura3-52 leu2-112 trp1-289) to create strain SUC-194, overexpressing PCKm, delta12NMDH2, FUMR, FRDm1 and SpMAE1. All genes were codon pair optimized for expression in S. cerevisiae.
- The expression vectors were transformed into yeast by electroporation. The transformation mixtures were plated on Yeast Nitrogen Base (YNB) w/o AA (Difco) + 2% glucose. Strains SUC-101 is described in Table 2.
Table 3: Yeast strains constructed for Example 2D. Name Background Plasmids Genes SUC-132 CEN.PK113-6B pGBS414PEK-2 PCKm, FRDm1 pGBS415FUM-2 FUMR, Δ12NMDH2 pRS416 (empty vector) SUC-194 CEN.PK113-6B pGBS414PEK-2 PCKm, FRDm1 pGBS415FUM-2 FUMR, Δ12NMDH2 pRS416MAE-1 SpMAE1 - Growth parameters and sample analysis were performed as described under example 2C.4 with the following modifications: pre-culturing was performed using 2% glucose (w/v) as carbon source. In the
production medium 10% glucose (w/v) was used as carbon source. - Strains transformed with empty vectors (control strain) produced up to 0.3 g/L succinic acid. Additional overexpression of SpMAE1 in strain SUC-194, overexpressing PCKm, delta12NMDH2, FUMR and FRDm1 resulted in increased succinic acid production levels to 4.6 g/L, whereas strain SUC-132, overexpressing PCKm, delta12NMDH2, FUMR and FRDm1 resulted in production of 2.7 g/L succinic acid.
- The results show that insertion of a malate transporter in a S. cerevisiae comprising the genetic modifications as described herein further increased succinic acid production at least 1.5 times.
- Described under 2D.1.
- Described under 2D.2.
- Plasmids pGBS414PPK-3, pGBS415FUM-3 and pGBS416MAE-1 (described under 2C.2.) were transformed into S. cerevisiae strain RWB064 (MATA ura3-52 leu2-112 trp1-289 adh1::lox adh2::lox gpd1::Kanlox) to create strain SUC-201, overexpressing PCKa, MDH3, FUMR, FRDg and SpMAE1. All genes were codon pair optimized for expression in S. cerevisiae.
Table 4: Yeast strains constructed for Example 2E. Name Background Plasmids Genes SUC-200 CEN.PK113-6B pGBS414PPK-3 PCKa, FRDg adh1::lox adh2::lox gpd1::Kanlox pGBS415FUM-3 FUMR, MDH3 pGBS416MAE-1 SpMAE1 SUC-201 CEN.PK113-6B pGBS414PPK-3 PCKa, FRDg adh1::/ox adh2::lox gpd1:: Kanlox pGBS415FUM-3 FUMR MDH3 pRS416 (empty vector) SUC-103 CEN.PK113-6B pRS414 (empty vector) adh1::lox adh2::lox gpd1::Kanlox pRS415 (empty vector) pRS415 (empty vector) - Growth parameters and sample analysis were performed as described under example 2C.4 with the following modifications: pre-culturing was performed using 2% galactose (w/v) as carbon source. 5% galactose (w/v) was added to the production medium at t=0, 3 and 7 days.
- Strain SUC-103 transformed with empty vectors (control strain) produced 0.9 g/L succinic acid after growth for 10 days in production medium (
Figure 20 ). Overexpression of PCKa, MDH3, FUMR and FRDg in strain RWB064 resulted in increased succinic acid production levels to 2.5 g/L (strain SUC-201,Figure 20 ). Additional overexpression of SpMAE1 besides PCKa, MDH3, FUMR and FRDg in strain RWB064 resulted in a further increase of succinic acid production levels to 11.9 g/L (strain SUC-200,Figure 20 ). - The results show that overexpression of a malate transporter in s S. cerevisiea comprising a deletion of alcohol dehydrogenase and glycerol-3-phosphate dehydrogenase genes resulted in a significant increase in succinic acid production levels. In addition it was shown that deletion of the gene adh1, adh2 and gpd1 (SUC 103) resulted in increased succinic acid production levels as compare to a wild type strain (SUC 101, Table 2).
- Gene sequences of PEP carboxykinase from A. succinogenes, malate dehydrogenase from S. cerevisiae, fumarase from R. oryzae and fumarate reductase from T. brucei are described under 2F.1. Cytoplasmic pyruvate carboxylase from Saccharomyces cerevisiae (Pyc2p) [E.C. 6.4.1.1.], GenBank accession number 1041734, SEQ ID NO: 41, is encoded by the nucleotide sequence SEQ ID NO: 42. Genomic DNA from S. cerevisiae strain CEN.PK113-5D (MATA ura3-52) was used as template to amplify the PYC2 coding sequence (SEQ ID NO: 42), using primers P1 (SEQ ID NO: 43) and P2 (SEQ ID NO: 44), and the Phusion DNA polymerase (Finnzymes, Finland) according to manufacturer's instructions. Convenient restriction sites were included in the primers for further cloning purposes.
- The expression construct pGBS426PYC-2 (
Figure 21 ) was created after a Spel/Xhol restriction of the S. cerevisiae expression vector p426GPD (Mumberg et al., Gene. 1995 ) and subsequently ligating in this vector a Spel/Xhol restriction fragment consisting of the amplified PYC2 nucleotide sequence (SEQ ID NO: 42). The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS426PYC-2 (Figure 21 ). Construction of expression vectors pGBS414PPK-3 and pGBS415FUM-3 is described under 2C.2. Expression construct pGBS414FRE-1 was created after a BamHI/NotI restriction of the S. cerevisiae expression vector pRS414 (Sirkoski R.S. and Hieter P, Genetics, 1989, 122(1):19-27) and subsequently ligating in this vector a BamHI/NotI restriction fragment consisting of the glycosomal fumarate reductase (origin Trypanosoma brucei) synthetic gene construct (SEQ ID NO: 35). The ligation mix was used for transformation of E. coli TOP10 (Invitrogen) resulting in the yeast expression construct pGBS414FRE-1 (Figure 22 ). - Strains SUC-226, SUC-227, SUC-228 and SUC-230 were obtained by transformation of different combinations of the plasmids pGBS414FRE-1, pGBS414PPK-3, pGBS415FUM-1, pGBS426PYC-2 and p426GPD into stain CEN.PK113-6B (MATA ura3-52 leu2-112 trp1-289), as depicted in Table 5.
Table 5: Yeast strains constructed for Example 2F. Name Background Plasmids Genes SUC-226 CEN.PK113-6B pGBS414PPK-3 PCKa, FRDg pGBS415FUM-3 FUMR, MDH3 p426GPD (empty vector) SUC-227 CEN.PK113-6B pGBS414PPK-3 PCKa, FRDg pGBS415FUM-3 FUMR, MDH3 pGBS426PYC-2 PYC2 SUC-228 CEN.PK113-6B pGBS414FRE-1 FRDg pGBS415FUM-3 FUMR, MDH3 pGBS426PYC-2 PYC2 SUC-230 CEN.PK113-6B pGBS414FRE-1 FRDg pGBS415FUM-3 FUMR, MDH3 p426GPD (empty vector) - Growth parameters and sample analysis were performed as described under example 2C.4 with the following modifications: pre-culturing was performed using 2% glucose (w/v) as carbon source. In the
production medium 10% glucose (w/v) was used as carbon source. - As depicted in
Figure 23 strain SUC-230, overexpressing MDH3, FUMR and FRDg, produced up to 3.0 g/L succinic acid. Additional overexpression of PCKa increased succinic acid production up to 3.4 g/L (strain SUC-226), and additional overexpression of PYC2 increased succinic acid production up to 3.7 g/L (strain SUC-228). Surprisingly, overexpression of both PCKa and PYC2 (SUC-227) resulted in 1.5 increase of succinic acid production levels up to 5.0 g/L, as compared to the effect of PCK and PYC alone. These results show a synergistic effect of combined overexpression of both PEP carboxykinase from A. succinogenes (PCKa) and pyruvate carboxylase from S. cerevisiae (PYC2) on succinic acid production levels in S. cerevisiae. - Genomic DNA of Aspergillus niger strain CBS513.88 was sequenced and analyzed. Two genes with translated proteins annotated as homologues to succinate dehydrogenase proteins were identified and named sdhA and sdhB respectively. Sequences of the sdhA (An16g07150) and sdhB (An02g12770) loci are available on genbank with accession numbers 145253004 and 145234071 respectively. Gene replacement vectors for sdhA and sdhB were designed according to known principles and constructed according to routine cloning procedures (see
figure 6 ). The vectors comprise approximately 1000 bp flanking regions of the sdh ORFs for homologous recombination at the predestined genomic loci. In addition, they contain the A. nidulans bi-directional amdS selection marker driven by the gpdA promoter, in-between direct repeats. The general design of these deletion vectors were previously described inEP635574B WO 98/46772 - Linear DNA of deletion vector pDEL-SDHA (
figure 4 ) was isolated and used to transform Aspergillus niger CBS513.88 as described in: Biotechnology of Filamentous fungi: Technology and Products. (1992) Reed Publishing (USA); Chapter 6: Transformation p. 113 to 156. This linear DNA can integrate into the genome at the sdhA locus, thus substituting the sdhA gene by the amdS gene as depicted infigure 6 . Transformants were selected on acetamide media and colony purified according to standard procedures as described inEP635574B - Strain dSDHA was selected as a representative strain with the sdhA gene inactivated. The succinic acid production of dSDHA was determined in microtiterplates as described in Example 4.
- A. niger strain dSDHA of example 3.2. was transformed with the expression construct pGBTOPAn1 (
Figure 5 ) comprising truncated mitochondrial fumarate reductase m1 (FRDm1, SEQ ID NO:7) as described in Example 1.1. E. coli DNA was removed by NotI digestion. A. niger transformants were picked using Qpix and transferred onto MTP's containing Aspergillus selective media. After 7 days incubation at 30 degrees Celsius the biomass was transferred to microtiter plates (MTP's) containing PDA by hand or colony picker. After 7 days incubation at 30 degrees Celsius, the biomass was sporulated. These spores were resuspended using the Multimek 96 (Beckman) in 100 microlitres minimal enriched Aspergillus medium containing 10% glucose. Subsequently 2 MTP with 170 micolitres minimal enriched Aspergillus medium containing 10% glucose and 1 % CaCO3 were inoculated with 30 microlitres of the spore suspension. Likewise, A. niger strains dSDHA and CBS513.88 were inoculated in the MTP's. These MTP's were incubated for 5 days at 34 degrees Celsius80% humidity. After 5 days 160 microlitres were harvested using the Multimek 96 (Beckman) and succinic acid was determined by HPLC as described in Example 1.4. The results are shown in Table 6.Table 6: Effect of deletion of succinate dehydrogenase (SDHA) and insertion of mitochondrial fumarate reductase (FRDm1) from T. brucei in A. niger on succinic acid production levels. A. niger strain Succinic acid mg/l CBS513.88 38 dSDHA 50 dSDHA, + gGBTOPAn1 (FRDm1) 583 - Table 6 clearly shows an increased production of succinic acid by A. niger that comprises mitochondrial fumarate reductase from T. brucei
-
- <110> DSM IP Assets BV Wu, Liang Damveld, Robbert Antonius Verwaal, René Sagt, Cornelis Maria Jacobus
- <120> Succinic acid production in a eukaryotic cell
- <130> 26345WO
- <140> 26345WO
<141> 2008-11-14 - <160> 44
- <170> PatentIn version 3.2
- <210> 1
<211> 1232
<212> PRT
<213> Trypanosoma brucei - <400> 1
- <210> 2
<211> 3698
<212> DNA
<213> Trypanosoma brucei - <400> 2
- <210> 3
<211> 1164
<212> PRT
<213> Artificial sequence - <220>
<223> FRDm Trypanosoma lacking 68 aa targeting signal - <400> 3
- <210> 4
<211> 1142
<212> PRT
<213> Trypanosoma brucei - <400> 4
- <210> 5
<211> 3429
<212> DNA
<213> Trypanosoma brucei - <400> 5
- <210> 6
<211> 1139
<212> PRT
<213> Artificial sequence - <220>
<223> FRDg lacking 3 aa C-terminal targeting signal - <400> 6
- <210> 7
<211> 3498
<212> DNA
<213> Artificial sequence - <220>
<223> FRDm1 codon optimised for A. niger - <400> 7
- <210> 8
<211> 3420
<212> DNA
<213> Artificial sequence - <220>
<223> FRDg gene optimised for A. niger - <400> 8
- <210> 9
<211> 3498
<212> DNA
<213> Artificial sequence - <220>
<223> FRDm1 gene optimsied for S. cerevisiae - <400> 9
- <210> 10
<211> 3420
<212> DNA
<213> Artificial sequence - <220>
<223> FRDg gene optimised for S. cerevisiae - <400> 10
- <210> 11
<211> 898
<212> DNA
<213> Artificial sequence - <220>
<223> GPDA promotor - <400> 11
- <210> 12
<211> 1000
<212> DNA
<213> Artificial sequence - <220>
<223> TDH3 promotor - <400> 12
- <210> 13
<211> 500
<212> DNA
<213> Artificial sequence - <220>
<223> TDH3 terminator - <400> 13
- <210> 14
<211> 538
<212> PRT
<213> Artificial sequence - <220>
<223> A. succinogenes PEP carboxykinase wherein EGY at position 120-122 is replaced by DAF - <400> 14
- <210> 15
<211> 1617
<212> DNA
<213> Artificial sequence - <220>
<223> nt. A. succinogenes PEP carboxykinase encoding DAF instead of EGY - <400> 15
- <210> 16
<211> 1617
<212> DNA
<213> Codon pair optimised A. succinogenes PEPCK for S. cerevisiae - <400> 16
- <210> 17
<211> 538
<212> PRT
<213> Mannheimia succinicipoducens - <400> 17
- <210> 18
<211> 1617
<212> DNA
<213> Artificial sequence - <220>
<223> PEPcarboxykinase M. succiniciproducens cpo for S. cerevisiae - <400> 18
- <210> 19
<211> 365
<212> PRT
<213> Artificial sequence - <220>
<223> MDH2 S. cerevisiae lacking first 12 a.a. - <400> 19
- <210> 20
<211> 1099
<212> DNA
<213> Artificial sequence - <220>
<223> cpo MDH2 S. cerevisiae lacking fisrt 12 a.a. - <400> 20
- <210> 21
<211> 340
<212> PRT
<213> Artificial sequence - <220>
<223> MDH3 S. cerevisiae lacking C-terminal SKL - <400> 21
- <210> 22
<211> 1024
<212> DNA
<213> Artificial sequence - <220>
<223> MDH3 S. cerevisiae lacking SKL encoding nt, cpo - <400> 22
- <210> 23
<211> 472
<212> PRT
<213> Artificial sequence - <220>
<223> Fumarase R. oryzae lacking first 23 aa+ new M - <400> 23
- <210> 24
<211> 1419
<212> DNA
<213> Artificial sequence - <220>
<223> Fumarase R. oryzae lacking nt encoding first aa + M - <400> 24
- <210> 25
<211> 1000
<212> DNA
<213> Artificial sequence - <220>
<223> TDH1 promotor - <400> 25
- <210> 26
<211> 500
<212> DNA
<213> Artificial sequence - <220>
<223> TDH1 terminator - <400> 26
- <210> 27
<211> 600
<212> DNA
<213> Artificial sequence - <220>
<223> second TDH3 promotor - <400> 27
- <210> 28
<211> 300
<212> DNA
<213> Artificial sequence - <220>
<223> second TDH3 terminator - <400> 28
- <210> 29
<211> 3148
<212> DNA
<213> Artificial sequence - <220>
<223> TDH1p-PCKm-TDH1t synthetic construct - <400> 29
- <210> 30
<211> 3148
<212> DNA
<213> Artificial sequence - <220>
<223> TDH1p-PCK1-TDH1t synthetic construct - <400> 30
- <210> 31
<211> 2637
<212> DNA
<213> Artificial sequence - <220>
<223> TDH3p-delta 12N MDH2-TDH3t synthetic construct - <400> 31
- <210> 32
<211> 1966
<212> DNA
<213> Artificial sequence - <220>
<223> TDH3p-MDH3-TDH3t synthetic construct - <400> 32
- <210> 33
<211> 2950
<212> DNA
<213> Artificial sequence - <220>
<223> TDH1-FUMR-TDH1t synthetic construct - <400> 33
- <210> 34
<211> 5037
<212> DNA
<213> Artificial sequence - <220>
<223> TDH3p-FRDm1-TDH3t synthetic construct - <400> 34
- <210> 35
<211> 4959
<212> DNA
<213> Artificial construct - <220>
<223> TDH3p-FRDg-TDH3t artificial sequence - <400> 35
- <210> 36
<211> 438
<212> PRT
<213> Schizosaccharomyces pombe - <400> 36
- <210> 37
<211> 1317
<212> DNA
<213> Artificial sequence - <220>
<223> S. pombe malae permease cpo for S. cerevisiae - <400> 37
- <210> 38
<211> 600
<212> DNA
<213> Artificial sequence - <220>
<223> ENO1 promotor T at position -5 was changed to A in order to obtain a better Kozak sequence - <400> 38
- <210> 39
<211> 300
<212> DNA
<213> Artificial sequence - <220>
<223> ENO1 terminator - <400> 39
- <210> 40
<211> 2240
<212> DNA
<213> Artificial sequence - <220>
<223> ENO1p-SpMAE-ENO1t synthetic construct - <400> 40
- <210> 41
<211> 1180
<212> PRT
<213> Saccharomyces cerevisiae - <400> 41
- <210> 42
<211> 3543
<212> DNA
<213> Saccharomyces cerevisiae - <400> 42
- <210> 43
<211> 30
<212> DNA
<213> Artificial sequence - <220>
<223> P1 primer - <400> 43
ggactagtat gagcagtagc aagaaattgg 30 - <210> 44
<211> 31
<212> DNA
<213> Artificial sequence - <220>
<223> P2 primer - <400> 44
ccgctcgagt tacttttttt gggatggggg t 31
Claims (15)
- A recombinant eukaryotic cell selected from the group consisting of a yeast and a filamentous fungus comprising a nucleotide sequence encoding a NAD(H)-dependent fumarate reductase that catalyses the conversion of fumaric acid to succinic acid, wherein the NAD(H)-dependent fumarate reductase is active in the cytosol upon expression of the nucleotide sequence encoding NAD(H)-dependent fumarate reductase.
- A cell according to claim 1, wherein the cell expresses a nucleotide sequence encoding an enzyme that catalyses the formation of succinic acid, wherein the nucleotide sequence encodes a NAD(H)-dependent fumarate reductase, comprising an amino acid sequence that has at least 40% sequence identity with the amino acid sequence of SEQ ID NO: 3, and/or SEQ ID NO: 6.
- A cell according to claim 1 or 2 wherein the NAD(H)-dependent fumarate reductase is derived from a Trypanosoma sp.
- A cell according to any one of the claims 1 to 3, wherein the cell further overexpresses a nucleotide sequence encoding a pyruvate carboxylase.
- A cell according to any one of the claims 1 to 4, further comprising a nucleotide sequence encoding a heterologous phosphoenolpyruvate carboxykinase.
- A cell according to any one of the claims 1 to 5, further comprising a nucleotide sequence encoding a malate dehydrogenase active in the cytosol upon expression of the nucleotide sequence encoding malate dehydrogenase.
- A cell according to any one of the claims 1 to 6, further comprising a nucleotide sequence encoding an enzyme that catalyses the conversion of malic acid to fumaric acid in the cytosol, upon expression of the nucleotide sequence encoding enzyme that catalyses the conversion of malic acid to fumaric acid.
- A cell according to any of the claims 1 to 7 further comprising a nucleotide sequence encoding a dicarboxylic acid transporter.
- A cell according to any one of the claims 1 to 8, wherein at least one gene encoding alcohol dehydrogenase is not functional.
- A cell according to any one of the claims 1 to 9, wherein at least one gene encoding glycerol-3-phosphate dehydrogenase is not functional.
- A cell according to any one of the claims 1 to 10, wherein at least one gene encoding succinate dehydrogenase is not functional.
- A cell according to any one of the claims 1 to 11, which is an Aspergillus, preferably an Aspergillus niger.
- A cell according to any one of the claims 1 to 11, which is a Saccharomyces cerevisiae
- A process for the preparation of succinic acid, comprising fermenting a eukaryotic cell according to any one of the claims 1 to 13 in a suitable fermentation medium, wherein succinic acid is prepared.
- A fermentation broth comprising succinic acid, wherein the fermentation broth is obtainable by the process according to claim 14.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13170415.7A EP2687602A1 (en) | 2007-11-20 | 2008-11-14 | Succinic acid production in a eukaryotic cell |
EP08851178.7A EP2220232B1 (en) | 2007-11-20 | 2008-11-14 | Succinic acid production in a eukaryotic cell |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07121113 | 2007-11-20 | ||
EP07121120 | 2007-11-20 | ||
EP07121117 | 2007-11-20 | ||
EP08156959 | 2008-05-27 | ||
EP08156961 | 2008-05-27 | ||
EP08156960 | 2008-05-27 | ||
PCT/EP2008/065583 WO2009065778A1 (en) | 2007-11-20 | 2008-11-14 | Succinic acid production in a eukaryotic cell |
EP08851178.7A EP2220232B1 (en) | 2007-11-20 | 2008-11-14 | Succinic acid production in a eukaryotic cell |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13170415.7A Division EP2687602A1 (en) | 2007-11-20 | 2008-11-14 | Succinic acid production in a eukaryotic cell |
EP13170415.7A Division-Into EP2687602A1 (en) | 2007-11-20 | 2008-11-14 | Succinic acid production in a eukaryotic cell |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2220232A1 EP2220232A1 (en) | 2010-08-25 |
EP2220232B1 true EP2220232B1 (en) | 2014-09-03 |
Family
ID=40268299
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08851178.7A Active EP2220232B1 (en) | 2007-11-20 | 2008-11-14 | Succinic acid production in a eukaryotic cell |
EP08851601A Active EP2220233B1 (en) | 2007-11-20 | 2008-11-14 | Dicarboxylic acid production in eukaryotes |
EP13170415.7A Withdrawn EP2687602A1 (en) | 2007-11-20 | 2008-11-14 | Succinic acid production in a eukaryotic cell |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08851601A Active EP2220233B1 (en) | 2007-11-20 | 2008-11-14 | Dicarboxylic acid production in eukaryotes |
EP13170415.7A Withdrawn EP2687602A1 (en) | 2007-11-20 | 2008-11-14 | Succinic acid production in a eukaryotic cell |
Country Status (10)
Country | Link |
---|---|
US (3) | US9340804B2 (en) |
EP (3) | EP2220232B1 (en) |
JP (2) | JP5641938B2 (en) |
CN (3) | CN101978063B (en) |
AT (1) | ATE555203T1 (en) |
BR (2) | BRPI0819275B8 (en) |
CA (2) | CA2704654C (en) |
EA (1) | EA032726B1 (en) |
ES (2) | ES2522622T3 (en) |
WO (2) | WO2009065780A1 (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2158323A4 (en) * | 2007-05-18 | 2011-06-22 | Microbia Prec Engineering Inc | Organic acid production by fungal cells |
ATE555203T1 (en) * | 2007-11-20 | 2012-05-15 | Dsm Ip Assets Bv | DICARBONIC ACID PRODUCTION IN EUKARYONES |
CA2714088A1 (en) * | 2008-02-15 | 2009-08-20 | Dsm Ip Assets B.V. | Process for the production of a dicarboxylic acid |
WO2010003728A1 (en) | 2008-07-08 | 2010-01-14 | Dsm Ip Assets B.V. | Dicarboxylic acid production by fermentation at low ph |
RU2422526C2 (en) | 2009-01-30 | 2011-06-27 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов (ФГУП ГосНИИгенетика) | METHOD OF PRODUCING SUCCINIC ACID WITH USING Yarrowia YEAST |
WO2010118932A1 (en) * | 2009-04-15 | 2010-10-21 | Dsm Ip Assets B.V. | Dicarboxylic acid production process |
UA108853C2 (en) | 2009-07-10 | 2015-06-25 | Galactose fermentation method | |
ES2655308T3 (en) | 2009-08-27 | 2018-02-19 | Dsm Ip Assets B.V. | Dicarboxylic acid fermentation procedure |
MX2012002532A (en) * | 2009-09-01 | 2012-04-11 | Novozymes Inc | Methods for improving malic acid production in filamentous fungi. |
US20120238722A1 (en) | 2009-11-24 | 2012-09-20 | Roquette Freres Sa | Process for the crystallization of succinic acid |
JP2011120508A (en) * | 2009-12-09 | 2011-06-23 | Oji Paper Co Ltd | Method for producing succinic acid |
CN102781900A (en) | 2009-12-31 | 2012-11-14 | 麦兰特公司 | Purification of succinic acid from the fermentation broth containing ammonium succinate |
CN102812127B (en) | 2010-03-09 | 2014-12-03 | 三菱化学株式会社 | Method of producing succinic acid |
EP2371802A1 (en) | 2010-03-30 | 2011-10-05 | DSM IP Assets B.V. | Process for the crystallization of succinic acid |
DK2561064T3 (en) | 2010-04-21 | 2018-01-15 | Dsm Ip Assets Bv | Cell which is suitable for fermentation of a composition of mixed sugars |
EP2576606B1 (en) | 2010-06-04 | 2014-12-10 | Novozymes, Inc. | C4 dicarboxylic acid production in filamentous fungi |
US8497103B2 (en) | 2010-06-21 | 2013-07-30 | Novozymes, Inc. | Methods for C4-dicarboxylic acid production in filamentous fungi |
EP2582716A1 (en) | 2010-06-21 | 2013-04-24 | Novozymes, Inc. | Aspergillus aculeatus derived polypeptides having c4-dicarboxylic acid transporter activity and polynucleotides encoding same |
WO2012031079A2 (en) * | 2010-09-01 | 2012-03-08 | University Of Florida Research Foundation, Inc. | L-malate production by metabolically engineered escherichia coli |
CN103228791B (en) | 2010-09-24 | 2016-06-15 | 帝斯曼知识产权资产管理有限公司 | Dicarboxylic acid production technique |
CN103314098A (en) | 2010-10-28 | 2013-09-18 | 道达尔炼油与销售部 | Use of monascus in organic acid production |
EP2495304A1 (en) | 2010-12-03 | 2012-09-05 | DSM IP Assets B.V. | Dicarboxylic acid production in a yeast cell |
EP2668281A4 (en) | 2011-01-25 | 2015-08-26 | Cargill Inc | Compositions and methods for succinate production |
CN103492551A (en) | 2011-02-28 | 2014-01-01 | 诺维信股份有限公司 | Microorganism for c4-dicarboxylic acid production |
EP2726624B1 (en) | 2011-07-01 | 2016-11-30 | DSM IP Assets B.V. | Process for producing dicarboxylic acids employing fungal cells |
BR112014003444A2 (en) | 2011-08-19 | 2017-03-14 | Novozymes Inc | recombinant host cell, and method for producing a c4-dicarboxylic acid |
CN102559518B (en) * | 2011-12-20 | 2013-10-16 | 江南大学 | High-yield fumaric acid Rhizopus delemar and application thereof |
WO2013112939A2 (en) * | 2012-01-25 | 2013-08-01 | Cargill, Incorporated | Methods for succinate production |
FR2987678B1 (en) | 2012-03-02 | 2016-04-15 | Roquette Freres | METHOD FOR MEASURING THE THERMAL STABILITY OF A CRYSTALLINE SUCCINIC ACID FOR THE MANUFACTURE OF POLYMERS |
FR2988733B1 (en) | 2012-03-27 | 2016-02-05 | Carbios | RECOMBINANT MICROORGANISM |
KR101464656B1 (en) * | 2012-06-15 | 2014-12-02 | 한국생명공학연구원 | Varient Microorganism Having Metabolites Producing Ability and Method for Preparing Metabolites Using the Same |
WO2014018755A1 (en) | 2012-07-25 | 2014-01-30 | Cargill Incorporated | Yeast cells having nadp(h)-dependent reductive tca pathway from pyruvate to succinate |
BR112015001601A2 (en) | 2012-07-25 | 2017-11-07 | Bioamber Sas | yeast cells having pyruvate reducing tca course in succinate and overexpression of a nad (p) + exogenous transhydrogenase enzyme |
WO2014036140A2 (en) * | 2012-08-28 | 2014-03-06 | Braskem S/A Ap 09 | Methods for production of a terpene and a co-product |
JP2015528312A (en) * | 2012-09-14 | 2015-09-28 | ミリアント・コーポレイションMyriant Corporation | Production of organic acids by fermentation under low pH conditions |
WO2014047407A1 (en) | 2012-09-20 | 2014-03-27 | Bioamber Inc. | Pathways to adipate semialdehyde and other organic products |
WO2014135712A2 (en) | 2013-03-08 | 2014-09-12 | Dsm Ip Assets B.V. | Polyester |
CN105378093A (en) * | 2013-07-18 | 2016-03-02 | 帝斯曼知识产权资产管理有限公司 | Fermentation process |
CA2931591C (en) | 2013-12-12 | 2023-09-19 | Dsm Ip Assets B.V. | Fumarate reductases |
JP6620373B2 (en) * | 2014-06-30 | 2019-12-18 | Jmtcエンザイム株式会社 | Transformant, method for producing the same, and method for producing dicarboxylic acid having 4 carbon atoms |
US9882151B2 (en) | 2014-11-14 | 2018-01-30 | Universal Display Corporation | Organic electroluminescent materials and devices |
EP3227256B1 (en) | 2014-12-02 | 2019-03-13 | Roquette Freres | Process for manufacturing succinic acid from a fermentation broth using nanofiltration to purify recycled mother liquor |
EP3067378A1 (en) | 2015-03-11 | 2016-09-14 | DSM IP Assets B.V. | Polyester |
US20180179499A1 (en) | 2015-06-04 | 2018-06-28 | Bioamber Inc. | Biobased production of functionalized alpha-substituted acrylates and c4-dicarboxylates |
PL3394251T3 (en) * | 2015-12-23 | 2023-05-02 | Technip Energies France S.A.S. | Host cells for dicarboxylic acid production |
JP2017121184A (en) * | 2016-01-04 | 2017-07-13 | 花王株式会社 | Mutant rhizopus bacteria |
CA3030605A1 (en) | 2016-07-13 | 2018-01-18 | Dsm Ip Assets B.V. | Malate dehyrogenases |
DE102016115425A1 (en) * | 2016-08-19 | 2018-02-22 | Jacobs University Bremen Ggmbh | Genetically modified yeast for the fermentation of glycerol |
US11548980B2 (en) | 2017-05-18 | 2023-01-10 | Avantium Knowledge Centre B.V. | Polyester copolymer |
CN110914335A (en) | 2017-05-18 | 2020-03-24 | 阿凡田知识中心有限公司 | Polyester copolymer |
WO2019011945A1 (en) * | 2017-07-11 | 2019-01-17 | Adisseo France S.A.S. | Enhanced metabolite-producing yeast |
EP3802801A1 (en) * | 2018-05-25 | 2021-04-14 | Danisco US Inc. | Overexpression of fumarate reductase results in an increased fermentation rate in yeast |
KR102129379B1 (en) * | 2018-10-10 | 2020-07-02 | 한국과학기술원 | A recombinant microorganism into which a high activity malate dehydrogenase for producing succinic acid and a method for producing succinic acid using the same |
EP3883985A1 (en) | 2018-11-22 | 2021-09-29 | Avantium Knowledge Centre B.V. | Process for the production of one or more polyester copolymers, method for the preparation of one or more oligomers, oligomer composition and polyester copolymer |
CN113249238B (en) * | 2021-05-07 | 2022-08-23 | 江南大学 | Acid-resistant saccharomyces cerevisiae and application thereof in preparation of organic acid |
CN114806913B (en) * | 2022-04-15 | 2023-11-28 | 盛虹控股集团有限公司 | High-yield succinic acid yeast engineering strain with mitochondria positioning reduction TCA pathway, construction method and application thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3542861A1 (en) | 1985-12-04 | 1987-06-11 | Huels Chemische Werke Ag | METHOD FOR OBTAINING L-APPLE ACID |
US5643758A (en) * | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
WO1990014423A1 (en) | 1989-05-18 | 1990-11-29 | The Infergene Company | Microorganism transformation |
EP0481008B1 (en) | 1989-07-07 | 1997-11-12 | Unilever Plc | Process for preparing a protein by a fungus transformed by multicopy integration of an expression vector |
EP0635574B1 (en) | 1993-07-23 | 2003-04-23 | Dsm N.V. | Selection marker gene free recombinant strains, a method for obtaining them and the use of these strains |
AU7642298A (en) | 1997-04-11 | 1998-11-11 | Gist-Brocades B.V. | Gene conversion as a tool for the construction of recombinant industrial filamentous fungi |
US6265186B1 (en) | 1997-04-11 | 2001-07-24 | Dsm N.V. | Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces |
BR9910532A (en) | 1998-05-19 | 2001-10-16 | Dsm Nv | Improved in vivo cephalosporin production |
CN1331751A (en) | 1998-12-22 | 2002-01-16 | Dsm公司 | Improved i(in vivo) prodn. of cephalosporins |
CN100575496C (en) * | 2003-08-28 | 2009-12-30 | 三菱化学株式会社 | Produce the method for succsinic acid |
DE102004011248A1 (en) * | 2004-03-09 | 2005-09-22 | Degussa Ag | Process for producing L-amino acids using coryneform bacteria |
CA2592449C (en) * | 2004-12-22 | 2015-11-24 | The Michigan Biotechnology Institute | Recombinant microorganisms for increased production of organic acids |
US7435168B2 (en) | 2005-01-14 | 2008-10-14 | Archer-Daniels-Midland Company | Compositions and methods for manipulating carbon flux in cells |
DE102005031801B3 (en) * | 2005-07-07 | 2006-08-24 | Carsten Paulsen | Cleaner for wind power generator tower has cleaning belt mounted on rollers and moved vertically of tower |
MX2008001716A (en) | 2005-08-05 | 2008-04-07 | Univ Michigan State | Genes from actinobacillus succinogenes 13oz (atcc 55618) for production of chemicals from the a. succinogenes c4-pathway. |
KR100727054B1 (en) | 2005-08-19 | 2007-06-12 | 한국과학기술원 | Microorganisms Transformed with Gene Encoding Fumarate Hydratase C and Method for Preparing Succinic Acid Using the Same |
CN101300356A (en) * | 2005-09-09 | 2008-11-05 | 基因组股份公司 | Methods and organisms for the growth-coupled production of succinate |
US20080090273A1 (en) | 2005-11-21 | 2008-04-17 | Aaron Adriaan Winkler | Malic Acid Production in Recombinant Yeast |
EP1867727A1 (en) | 2006-06-15 | 2007-12-19 | Danmarks Tekniske Universitet | Enhanced citrate production |
AU2007263880A1 (en) | 2006-06-29 | 2008-01-03 | Dsm Ip Assets B.V. | A method for achieving improved polypeptide expression |
JP5218400B2 (en) * | 2007-04-17 | 2013-06-26 | 味の素株式会社 | Method for producing an acidic substance having a carboxyl group |
EP2155885A4 (en) | 2007-05-18 | 2010-12-01 | Microbia Prec Engineering Inc | Malic acid production in recombinant yeast |
EP2158323A4 (en) | 2007-05-18 | 2011-06-22 | Microbia Prec Engineering Inc | Organic acid production by fungal cells |
ATE555203T1 (en) * | 2007-11-20 | 2012-05-15 | Dsm Ip Assets Bv | DICARBONIC ACID PRODUCTION IN EUKARYONES |
WO2013112939A2 (en) | 2012-01-25 | 2013-08-01 | Cargill, Incorporated | Methods for succinate production |
JP2015528312A (en) | 2012-09-14 | 2015-09-28 | ミリアント・コーポレイションMyriant Corporation | Production of organic acids by fermentation under low pH conditions |
-
2008
- 2008-11-14 AT AT08851601T patent/ATE555203T1/en active
- 2008-11-14 CN CN200880117129.3A patent/CN101978063B/en active Active
- 2008-11-14 ES ES08851178.7T patent/ES2522622T3/en active Active
- 2008-11-14 ES ES08851601T patent/ES2383473T3/en active Active
- 2008-11-14 EA EA201000837A patent/EA032726B1/en not_active IP Right Cessation
- 2008-11-14 EP EP08851178.7A patent/EP2220232B1/en active Active
- 2008-11-14 EP EP08851601A patent/EP2220233B1/en active Active
- 2008-11-14 CA CA2704654A patent/CA2704654C/en active Active
- 2008-11-14 BR BRPI0819275A patent/BRPI0819275B8/en active IP Right Grant
- 2008-11-14 EP EP13170415.7A patent/EP2687602A1/en not_active Withdrawn
- 2008-11-14 BR BRPI0819273A patent/BRPI0819273B8/en active IP Right Grant
- 2008-11-14 CA CA2875319A patent/CA2875319A1/en not_active Abandoned
- 2008-11-14 CN CN201510186003.3A patent/CN104818224A/en active Pending
- 2008-11-14 WO PCT/EP2008/065588 patent/WO2009065780A1/en active Application Filing
- 2008-11-14 US US12/743,927 patent/US9340804B2/en active Active
- 2008-11-14 US US12/743,106 patent/US20120165569A1/en not_active Abandoned
- 2008-11-14 JP JP2010533596A patent/JP5641938B2/en active Active
- 2008-11-14 CN CN200880117105.8A patent/CN101903522B/en active Active
- 2008-11-14 WO PCT/EP2008/065583 patent/WO2009065778A1/en active Application Filing
-
2013
- 2013-10-02 US US14/044,722 patent/US9689005B2/en active Active
-
2014
- 2014-07-25 JP JP2014151882A patent/JP2014236739A/en active Pending
Non-Patent Citations (2)
Title |
---|
CAMARASA C ET AL: "Role in anaerobiosis of the isoenzymes for Saccharomyces cerevisiae fumarate reductase encoded by OSM1 and FRDS1", YEAST, JOHN WILEY & SONS LTD, GB, vol. 24, no. 5, 1 May 2007 (2007-05-01), pages 391 - 401, XP002591397, ISSN: 0749-503X, [retrieved on 20070307], DOI: 10.1002/YEA.1467 * |
FUJIMAKI T: "Processability and properties of aliphatic polyesters, 'BIONOLLE', synthesized by polycondensation reaction", POLYMER DEGRADATION AND STABILITY, BARKING, GB, vol. 59, no. 1-3, 1 January 1998 (1998-01-01), pages 209 - 214, XP004294378, ISSN: 0141-3910, DOI: DOI:10.1016/S0141-3910(97)00220-6 * |
Also Published As
Publication number | Publication date |
---|---|
US20120165569A1 (en) | 2012-06-28 |
CA2704654C (en) | 2015-02-10 |
US20140031587A1 (en) | 2014-01-30 |
EP2687602A1 (en) | 2014-01-22 |
JP2014236739A (en) | 2014-12-18 |
BRPI0819275B1 (en) | 2022-05-17 |
CN101978063B (en) | 2018-10-16 |
EP2220233B1 (en) | 2012-04-25 |
CN101903522A (en) | 2010-12-01 |
BRPI0819275A2 (en) | 2014-10-14 |
CA2875319A1 (en) | 2009-05-28 |
BRPI0819273B8 (en) | 2022-07-19 |
BRPI0819273A2 (en) | 2014-10-14 |
US20110081694A1 (en) | 2011-04-07 |
WO2009065780A1 (en) | 2009-05-28 |
US9340804B2 (en) | 2016-05-17 |
EA201000837A1 (en) | 2010-12-30 |
ATE555203T1 (en) | 2012-05-15 |
BRPI0819275B8 (en) | 2022-07-19 |
BRPI0819273B1 (en) | 2022-05-17 |
US9689005B2 (en) | 2017-06-27 |
JP2011502524A (en) | 2011-01-27 |
EA032726B1 (en) | 2019-07-31 |
WO2009065778A1 (en) | 2009-05-28 |
JP5641938B2 (en) | 2014-12-17 |
ES2522622T3 (en) | 2014-11-17 |
EP2220232A1 (en) | 2010-08-25 |
CA2704654A1 (en) | 2009-05-28 |
CN104818224A (en) | 2015-08-05 |
CN101903522B (en) | 2015-08-05 |
CN101978063A (en) | 2011-02-16 |
EP2220233A1 (en) | 2010-08-25 |
ES2383473T3 (en) | 2012-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2220232B1 (en) | Succinic acid production in a eukaryotic cell | |
EP2220234B1 (en) | Dicarboxylic acid production in a recombinant yeast | |
US20110104771A1 (en) | Process for the production of a dicarboxylic acid | |
EP2495304A1 (en) | Dicarboxylic acid production in a yeast cell | |
US20140045230A1 (en) | Dicarboxylic acid production in a filamentous fungus | |
WO2014080024A2 (en) | Itaconic acid and itaconate methylester production | |
US20170191089A1 (en) | Itaconic acid and itaconate methylester and dimethylester production | |
EP3394251B1 (en) | Host cells for dicarboxylic acid production | |
WO2015181311A1 (en) | Process for producing itaconic acid and itaconic acid esters under anaerobic conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100617 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VERWAAL, RENE Inventor name: WU, LIANG Inventor name: SAGT, CORNELIS, MARIA, JACOBUS Inventor name: DAMVELD, ROBBERTUS, ANTONIUS |
|
17Q | First examination report despatched |
Effective date: 20110120 |
|
DAX | Request for extension of the european patent (deleted) | ||
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 9/02 20060101ALI20130212BHEP Ipc: C12P 7/46 20060101ALI20130212BHEP Ipc: C12N 15/53 20060101AFI20130212BHEP Ipc: C12N 1/19 20060101ALI20130212BHEP Ipc: C12N 1/15 20060101ALI20130212BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20140108 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20140606 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 685639 Country of ref document: AT Kind code of ref document: T Effective date: 20140915 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008034269 Country of ref document: DE Effective date: 20141016 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2522622 Country of ref document: ES Kind code of ref document: T3 Effective date: 20141117 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141204 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141203 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150105 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008034269 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141114 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141130 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141130 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141130 |
|
26N | No opposition filed |
Effective date: 20150604 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20081114 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140903 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230601 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20231026 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231019 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231212 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20231026 Year of fee payment: 16 Ref country code: FR Payment date: 20231024 Year of fee payment: 16 Ref country code: DE Payment date: 20231017 Year of fee payment: 16 Ref country code: AT Payment date: 20231025 Year of fee payment: 16 |